



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 217/04, A61K 31/47, C07D 217/02, 217/06, 409/12, 401/12, 417/12, 405/12, 413/12	A1	(11) International Publication Number: WO 98/41508 (43) International Publication Date: 24 September 1998 (24.09.98)
(21) International Application Number: PCT/GB98/00782 (22) International Filing Date: 16 March 1998 (16.03.98) (30) Priority Data: <div style="display: flex; justify-content: space-between;"> <div>9705619.6</div> <div>18 March 1997 (18.03.97)</div> <div>GB</div> </div> <div style="display: flex; justify-content: space-between;"> <div>9726695.1</div> <div>17 December 1997 (17.12.97)</div> <div>GB</div> </div> (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): THOMPSON, Mervyn [GB/GB]; (GB). WARD, Robert, William [GB/GB]; (GB). EDWARDS, Peter, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: WEST, Vivien; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS		
<div style="position: absolute; right: 0; top: 0;">(I)</div>		
(57) Abstract Compounds of formula (I) and pharmaceutically acceptable salts thereof; where Q is a monocyclic or bicyclic aryl or heteroaryl ring, R ¹ is hydrogen, C ₁₋₆ alkyl (optionally substituted by hydroxy or C ₁₋₄ alkoxy), C ₁₋₆ alkenyl, C ₁₋₆ alkynyl, C ₁₋₆ alkylCO-, formyl, CF ₃ CO- or C ₁₋₆ alkylSO ₂ -, R ² is hydrogen or up to three substituents selected from halogen, NO ₂ , CN, N ₃ , CF ₃ O-, CF ₃ S-, CF ₃ CO-, trifluoromethyldiaziriny, C ₁₋₆ alkyl, C ₁₋₆ alkenyl, C ₁₋₆ alkynyl, C ₁₋₆ perfluoroalkyl, C ₃₋₆ cycloalkyl, C ₃₋₆ cycloalkyl-C ₁₋₄ alkyl-, C ₁₋₆ alkylO-, C ₁₋₆ alkylCO-, C ₃₋₆ cycloalkylO-, C ₃₋₆ cycloalkylCO-, C ₃₋₆ cycloalkyl-C ₁₋₄ alkylO-, C ₃₋₆ cycloalkyl-C ₁₋₄ alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C ₁₋₄ alkyl-, C ₁₋₆ alkylS-, C ₁₋₆ alkylSO ₂ -, (C ₁₋₄ alkyl) ₂ NSO ₂ -, (C ₁₋₄ alkyl)NHSO ₂ -, (C ₁₋₄ alkyl) ₂ NCO-, (C ₁₋₄ alkyl)NHCO- or CONH ₂ ; or -NR ³ R ⁴ where R ³ is hydrogen or C ₁₋₄ alkyl, and R ⁴ is hydrogen, C ₁₋₄ alkyl, formyl, -CO ₂ C ₁₋₄ alkyl or -COC ₁₋₄ alkyl; or two R ² groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by -OH or =O; and X is hydrogen, halogen, C ₁₋₆ alkoxy, C ₁₋₆ alkyl, amino or trifluoroacetyl amino, but when X is hydrogen excluding compounds in which R ² is 2-alkoxy and when X is hydrogen excluding the compounds N-(7-iodo-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl) -5-benzoyl-2-methoxybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl) -5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl) -2-methoxy-4-trifluoromethyldiazirinybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl) -2-methoxy-5-trifluoromethyldiazirinybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl) -2-methoxy-5-trifluoromethyldiazirinybenzamide et N-(8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl) -4- <i>t</i> -butyl-2-methoxybenzamide, are useful <i>inter alia</i> in the treatment and prophylaxis of epilepsy.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS


This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.

5

WO97/48683 (SmithKline Beecham), unpublished at the filing date of this application, discloses tetrahydroisoquinoliny benzamides in which the benzamide moiety has a 2-alkoxy substituent, including the compounds: N-(7-iodo-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-4-trifluoromethyldiazirinybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-5-trifluoromethyldiazirinybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-2-methoxy-5-trifluoromethyldiazirinybenzamide and N-(8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-4-*t*-butyl-2-methoxybenzamide.

It has now been surprisingly found that carboxamide compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

Accordingly, the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:



where Q is a monocyclic or bicyclic aryl or heteroaryl ring,

5 R^1 is hydrogen, C_{1-6} alkyl (optionally substituted by hydroxy or C_{1-4} alkoxy), C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} alkylCO-, formyl, CF_3 CO- or C_{1-6} alkylSO₂-,

10 R^2 is hydrogen, hydroxy, or up to three substituents selected from halogen, NO₂, CN, N₃, CF_3 O-, CF_3 S-, CF_3 CO-, trifluoromethyldiazirinyl, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} perfluoroalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl-, C_{1-6} alkylO-, C_{1-6} alkylCO-, C_{3-6} cycloalkylO-, C_{3-6} cycloalkylCO-, C_{3-6} cycloalkyl- C_{1-4} alkylO-, C_{3-6} cycloalkyl- C_{1-4} alkylCO-, acetoxyl, phenyl, phenoxy, benzyloxy, benzoyl, phenyl- C_{1-4} alkyl-, C_{1-6} alkylS-, C_{1-6} alkylSO₂-, (C_{1-4} alkyl)₂NSO₂-, (C_{1-4} alkyl)NHSO₂-, (C_{1-4} alkyl)₂NCO-, (C_{1-4} alkyl)NHCO- or CONH₂;
 15 or -NR³R⁴ where R³ is hydrogen or C_{1-4} alkyl, and R⁴ is hydrogen, C_{1-4} alkyl, formyl, -CO₂ C_{1-4} alkyl or -COC C_{1-4} alkyl; or two R² groups together form a carbocyclic ring that is saturated or
 20 unsaturated and unsubstituted or substituted by -OH or =O; and

X is hydrogen, halogen, C_{1-6} alkoxy, C_{1-6} alkyl, amino or trifluoroacetyl amino; but when X is hydrogen excluding compounds in which R² is 2-alkoxy and when X is halogen excluding the compounds N-(7-iodo-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-4-trifluoromethyldiazirinylbenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-5-trifluoromethyldiazirinylbenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-2-methoxy-5-trifluoromethyldiazirinyl benzamide and N-(8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-4-*t*-butyl-2-methoxybenzamide.

25
30

The compounds of this invention are typically, (tetrahydroisoquinolin-7-yl) carboxamides, especially (tetrahydroisoquinolin-7-yl)benzamides. When the substituent X is not


hydrogen it may be at the 5, 6, or 8 position of the tetrahydroisoquinoline moiety, especially position 5.

The ring system Q is typically optionally substituted phenyl or optionally substituted heteroaryl, typically thiophenyl or 3-isoxazolyl. When two R^2 groups form a carbocyclic ring, this is typically a 5-7 membered ring, and Q may be a naphthalene or an indane or indanone ring system or a bicyclic heteroaryl such as 5-dihydrobenzofuranyl.


In the formula (I), alkyl groups, including alkyl groups that are part of other moieties, such as alkoxy or acyl, may be straight chain or branched. Phenyl groups, including phenyl groups that are part of other moieties, in R^2 may optionally be substituted with one or more independently selected from halogen or C_{1-6} alkyl, C_{1-6} alkoxy or C_{1-6} alkylcarbonyl.

Suitable C_{3-6} cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Suitable halo substituents include fluoro, chloro, iodo and bromo.

One suitable group of compounds of this invention are of formula (IA)



and another suitable group are of formula (IB)



30

A suitable group of compounds of formula (I) have

R^1 as hydrogen, methyl, ethyl, propyl, hydroxyethyl, methoxyethyl, formyl, acetyl, trifluoroacetyl or methanesulfonyl,

R^2 as hydrogen or one or more of methyl, ethyl, *n*-butyl, *iso*-propyl, *iso*-butyl, *t*-butyl, phenyl, methoxy, ethoxy, *iso*-propoxy, *n*-butoxy, cyclopropylmethoxy, phenoxy, benzyloxy, , amino, acetylamino, nitro, azido, cyano, bromo, chloro, fluoro, iodo, acetyl, pivaloyl, *iso*-butyryl, benzoyl, iodobenzoyl, trifluoromethyl, perfluoroethyl, trifluoromethoxy, trifluoroacetyl, trifluoromethyldiaziriny, methanesulfonyl, *n*-propylsulfonyl, isopropylsulfonyl, dimethylsulfamoyl; or two groups R^2 form a benzene, cyclopentane or cyclopentanone ring; X as hydrogen, chloro, bromo, iodo, fluoro, amino, trifluoroacetylamino.

A preferred group of compounds of formula (I) have

R^1 as hydrogen, methyl, methoxyethyl,
 R^2 as hydrogen or one or more of methyl, *n*-butyl, *t*-butyl, *iso*-propyl, phenyl, methoxy, ethoxy, *iso*-propoxy, phenoxy, acetyl, nitro, cyano, bromo, chloro, fluoro, iodo, pivaloyl, trifluoromethyl, azido, trifluoromethoxy.
 X as hydrogen, iodo, chloro, bromo or trifluoroacetylamino.

Examples of compounds of formula (I) are:

N-(1,2,3,4-tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide
 N-(2-methyl-1, 2, 3, 4-tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chlorobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*t*-butylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-nitrobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluorobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyanobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dichlorobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-iodobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-bromobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-nitrobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-butylbenzamide

- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-acetoxybenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoromethylbenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-difluorobenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dimethoxybenzamide
5 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-fluoro-4-trifluoromethyl benzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-nitrobenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-di-trifluoromethylbenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-dichloro-5-fluorobenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-5-trifluoromethyl benzamide
10 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4,5-trimethoxybenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethoxybenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-pivaloylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propoxybenzamide
15 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-acetoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopentyloxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopropylmethoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-naphthamide
20 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-naphthalene-1-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*tert*-butoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxybenzamide
25 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl) benzotriazole-5-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzothiazole-6-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,3-dihydrobenzofuran-5-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylbenzimidazole-5-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide
30 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-ethoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-methoxybenzamide
35 N-(2-Methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-ethoxybenzamide
N-(2-Methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-*iso*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonylbenzamide
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*tert*-butylbenzamide

- N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromo-5-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methoxybenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-1-methylpyrazole-4-carboxamide
5 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethylpyrazole-3-
carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylthiazole-4-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-methylisoxazole-3-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-*tert*-butylisoxazole-3-carboxamide
10 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methoxyisoxazole-5-carboxamide
hydrochloride
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)indole-2-carboxamide.
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propylbenzamide,
hydrochloride
15 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*n*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethoxybenzamide
20 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*n*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-iodo-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxy-3-trifluoromethyl
benzamide
25 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*tert*-butylbenzamide,
hydrochloride
30 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxybenzamide hydrochloride.
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethylbenzamide
35 hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propyl-3-trifluoromethyl-
benzamide hydrochloride

- N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-trifluoromethylbenzamide
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propoxybenzamide
hydrochloride
- 5 N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methyl-3-methylsulfonyl-benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-methylsulfonylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-*iso*-
propylbenzamide
- 10 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoroacetylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-pentafluoroethyl-
benzamide hydrochloride
- 15 N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-
trifluoromethylbenzamide
N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-butylbenzamide
- 20 hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-butyl-3-trifluoromethyl-
benzamide hydrochloride
N-(2-Ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-Ethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-4-methoxy-3-trifluoromethyl benzamide
- 25 N-(2-*iso*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-*iso*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxy-3-methylsulfonyl-benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-oxochroman-6-carboxamide
- 30 hydrochloride
N-(2-Formyl--1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-
trifluoromethylbenzamide
N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide
- 35 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenylmethoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-hydroxy-3-trifluoromethyl benzamide

N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propoxybenzamide

N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide

5 N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide

N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide, trifluoroacetate

N-(2-Methyl-5-trifluoroacetylamino-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide

10 N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide

N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide

When synthesised, these compounds are often in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in
15 preparing pharmaceutically acceptable salts. The compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.

The above compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, form a
20 preferred aspect of the present invention.

The administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration.

25 An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be
30 administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6
35 mg/kg/day.

It is greatly preferred that the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, rectal, topical or parenteral (especially intravenous) composition.

Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusible solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colorants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving

the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

5

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the

10

compound of the invention.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

15

Accordingly, the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

20

25

30

The present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea,

35

schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.

10

In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

25


In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer

30


35

pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

- 5 Another aspect of the invention is a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (II)



where R^{1A} is R¹ as defined for formula (I) or a group convertible to R¹
and X is as defined in claim 1
with a compound of formula (III)



- 20 where Q is as defined in formula (I), Y is Cl or OH, and R^{2A} groups are independently R²
as defined for formula (I) or groups convertible to R²,
and where required converting an R^{1A} or R^{2A} group to a R¹ or R² group,
converting one R¹ or R² group to another R¹ or R² group,
converting a salt product to the free base or another pharmaceutically acceptable salt, or
25 converting a free base product to a pharmaceutically acceptable salt.

Reaction of a compound of formula (III) which is an acid chloride (Y=Cl) will lead directly to the hydrochloride salt. Suitable solvents include ethyl acetate or dichloromethane, optionally in the presence of a base such as triethylamine. When the
30 compound of formula (III) is an aromatic acid (Y=OH), conventional conditions for condensation of such acids with amines may be used, for example reacting the


components in a mixture of (dimethylaminopropyl)-ethyl-carbodiimide/hydroxybenzotriazole in a suitable solvent such as dimethyl formamide.

Conversions of an R^{1A} or R^{2A} group to a R^1 or R^2 group typically arise when a
 5 protecting group is needed during the above coupling reaction or during the preparation of
 the reactants by the procedures described below. Interconversion of one R^1 or R^2 group
 to another typically arises when one compound of formula (I) is used as the immediate
 precursor of another compound of formula (I) or when it is easier to introduce a more
 complex or reactive substituent at the end of a synthetic sequence.


10

Compounds of formula (II) in which X is hydrogen may be prepared from a nitro-tetrahydroisoquinoline of formula (IV).

15



by reaction with a compound $R^{1A}Z$ where Z is a leaving group such as halogen, especially
 iodo, or tosylate to obtain an intermediate of formula (V)



20

which can be reduced, for example using either tin (II) chloride and HCL or hydrogen and
 a palladium/activated carbon catalyst, to obtain an amino-tetrahydroisoquinoline of
 25 formula (II).


When the intended R^{1A} group is methyl, the compound of formula (IV) may also be
 reacted with formic acid and formaldehyde to introduce the N-methyl group.

30 The nitro-tetrahydroisoquinoline of formula (IV) may be prepared by hydrolysis of 2-
 trifluoroacetyl-nitro-tetrahydroisoquinoline obtained by reaction of an N-
 (nitrophenyl)ethyl-trifluoroacetamide and paraformaldehyde in acidic conditions using the
 procedure of Stokker, Tet.Lett.,1996, 37, 5453. N-(nitrophenyl)ethyl-trifluoroacetamides

can be prepared from readily available materials by reaction of trifluoroacetic anhydride with lutidine and nitrophenethylamine hydrochloride, as illustrated in the Descriptions below.

- 5 Compounds of formula (II) may also be prepared from the corresponding amino-isoquinoline (or its nitro-analogue) of formula (VI)


10



where R^N is NH_2 or NO_2

by reaction with a compound $R^{1A}Z$ where Z is a leaving group such as halogen, especially iodo, or tosylate to obtain an intermediate of formula (VII)

15



which can be reduced, for example using sodium borohydride, or hydrogenated, for example using hydrogen and a palladium/activated carbon catalyst, to obtain a tetrahydroisoquinoline of formula (II). When the compound of formula (VII) is replaced
20 by a nitro-isoquinoline, the nitro group is converted to an amino group in the hydrogenation step.

When the intended R^1 is hydrogen, the N of the tetrahydroisoquinoline or isoquinoline is preferably protected conventionally, prior to the coupling step that forms the carboxamide
25 of formula (I), for example by *tert*-butoxycarbonyl or trifluoroacetyl. The compound can be deprotected under standard conditions, for example using trifluoroacetic acid/methylene chloride.

Amino/nitro-isoquinolines of formulae (VI) and the reagents used are commercially
30 available, or can be prepared from commercially available materials using conventional procedures described in the literature.

When the substituent X is other than hydrogen it may be introduced during any of the procedures above, for example by conventional substitution of the aromatic ring of compounds of formula (IV), (V) or (VII) or may be present on commercially available starting materials usable in the above described procedures. Most suitably the substituent X is introduced to a compound of formula (II) in which X is hydrogen. For example X as halogen may be incorporated *via* an amino group using Sandmeyer chemistry as illustrated in the descriptions below.

Compounds of formula (III) may be prepared by further substitution of commercially available benzoic acid or thiophene carboxylic acid derivatives using conventional procedures, or by oxidation of corresponding substituted benzyl alcohols. Alternatively benzoic acids can be prepared from correspondingly substituted phenols, for example by formation of the acetate, conversion to an acetophenone and then to the desired acid.

Where the above described intermediates are novel compounds, they also form part of this invention.

The preparation of compounds of this invention is further illustrated by the following Descriptions and Examples. The utility of compounds of this invention is shown by the Pharmacological Data that follow the Examples.

Description 1

N-2-(4-Nitrophenyl)ethyl-trifluoroacetamide

A solution of trifluoroacetic anhydride (10.6ml) in dichloromethane (100ml) was added dropwise to a stirred solution of 2,6-lutidine (17.44ml) and 4-nitrophenethylamine hydrochloride (15.2g; 75 mmol) at 0°C. The mixture was stirred at 25°C overnight under argon and then washed with dilute citric acid (x2), brine and dried over Na₂SO₄. The material in the organic phase gave the title compound as a pale yellow solid (19.04g).

Description 2

7-Nitro-1,2,3,4-tetrahydro-2-trifluoroacetylisoquinoline

The nitro compound D1 (2.26g; 9.15 mmol) and paraformaldehyde (0.45g; 14.4 mmol) in acetic acid (10ml) and conc. H₂SO₄ (15ml) were stirred at 25°C for 20h according to the procedure of G.E. Stokker., Tet. Lett., 1996, 37, 5453. Work up afforded the title compound as a white solid (2.17g).

¹H NMR (CDCl₃) δ: 3.10 (2H, m), 3.92 (2H, m), 4.85 + 4.92 (2H, 2xs), 7.38 (1H, t), 8.10 (2H, m); ^{m/z} (EI): 274 (M⁺)

Description 3**7-Nitro-1,2,3,4-tetrahydroisoquinoline**

5 The trifluoroacetamide D2 (17.22g; 63 mmol) was hydrolysed at room temperature using a solution of potassium carbonate (46.6g) in 10% aqueous methanol (660ml). Work-up with dichloromethane gave the title compound (11g).

Description 4**2-Methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline**

10 The amine D3 (2.08g; 11.7 mmol) was treated with 88% formic acid (3.45ml) and 37% aqueous formaldehyde (5.88ml) at 80°C for 2h according to the procedure of G.M. Carrera and D.S. Garvey, J. Het. Chem., 1992, **29**, 847. Basification with 10% sodium hydroxide followed by work-up with ethyl acetate afforded an orange gum (2.3g). Chromatography on Kiesegel 60 in 0-3% methanol - ethyl acetate gave the title
15 compound as an orange solid (1.7g).

m/z (CI): 193 (MH⁺).

Description 5**7-Amino-2-methyl-1,2,3,4-tetrahydroisoquinoline**

20 The 7-nitro compound D4 (0.25g; 1.3 mmol) in methanol (40ml) was hydrogenated over 10% palladium on carbon (100mg) at atmospheric pressure overnight. The catalyst was removed by filtration through a pad of Kieselguhr and evaporation *in vacuo* gave the title compound as a white solid (213mg).

25

m/z (CI): 163 (MH⁺)

Description 6**7-Amino-2-(*t*-butyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline**

30 The title compound was prepared from the compound of Description D3 using di *t*-butyl dicarbonate in 10% aqueous hydroxide in dioxan at 25°C followed by catalytic hydrogenation according to the procedure described for D5.

Description 7**N-(2-*t*-Butyloxycarbonyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-5-chlorothiophene-2-carboxamide**

5-Chlorothiophene-2-carboxylic acid (214mg; 1.3mmol), ethyldimethylaminopropyl carbodiimide (250mg; 1.3mmol) and 1-hydroxybenzotriazole (176mg; 1.3 mmol) in dry DMF (25ml) was stirred at room temperature for 30 min. A solution of the N-boc amine D6 (300mg; 1.21mmol) in dichloromethane (5ml) was added and the mixture kept at room temperature overnight. Work-up gave a pink gum which was chromatographed on Kieselgel 60 in 30% ethyl acetate-hexane. Combination of appropriate fractions gave the title compound as an off white solid (0.5g).

¹H NMR (400MHz, CDCl₃) δ: 1.51 (9H, s), 2.82 (2H, t), 3.65 (2H, t), 4.56 (2H, s), 6.95 and 7.37 (2H, ABq), 7.12 (1H, d), 7.28 (1H, s), 7.46 (1H, br).

Description 8**7-Nitro-2-*n*-propyl-1,2,3,4-tetrahydroisoquinoline**

Nitro compound D3 (1.55g, 8.7mmol) and propionaldehyde (2.52g, 43.5mmol) in 1,2-dichloroethane (50ml) were treated with sodium triacetoxyborohydride (0.28g, 13.1 mmol) and glacial acetic acid (0.6ml, 9.0mmol). The mixture was stirred at 25°C over the weekend and then diluted with dichloromethane (50ml). The mixture was washed with saturated NaHCO₃, dried (Na₂SO₄) and evaporated *in vacuo*. Chromatography on Kieselgel 60 in ethyl acetate gave the title compound.

Description 9**7-Amino-2-*n*-propyl-1,2,3,4-tetrahydroisoquinoline**

The nitro compound D8 (0.73g, 3.32mmol) in ethanol (100ml) was heated to 50°C and treated with a solution of tin (II) chloride (2.52g, 13.27mmol) in conc. HCl (10ml) and stirring continued for 3h. The mixture was basified with 40% NaOH and the product extracted into dichloromethane. Work-up and chromatography on Kieselgel 60 in 10% methanol:dichloromethane gave the title compound as a viscous yellow oil (0.26g; 41%).

m/z (API⁺): 191 (MH⁺; 80%).

Description 10**7-Amino-2-*iso*-propyl-1,2,3,4-tetrahydroisoquinoline**

The title compound was prepared from D3 and acetone in 10% overall yield using a method similar to that described in Descriptions 8 and 9.

Description 11**7-Amino-2-ethyl-1,2,3,4-tetrahydroisoquinoline**

The title compound was prepared in 14% overall yield from D3 and acetaldehyde using a method similar to that described in Descriptions 5 and 8.

5

Description 12**2-Formyl-7-nitro-1,2,3,4-tetrahydroisoquinoline**

A mixture of acetic anhydride (1.4ml) and formic acid (0.7ml) was stirred at 50°C for 15 min. After cooling to 0°C, a solution of D3 (1.78g) and 4-dimethylaminopyridine (0.1g) in dichloromethane (30ml) was added and stirring continued at 25°C for 2h. The reaction mixture was washed with aq. potassium carbonate, water, brine and dried (MgSO₄). Evaporation *in vacuo* gave the title compound (2.4g).

¹H NMR (250 MHz, CDCl₃) δ: 3.0 (2H, m), 3.72(t) and 3.88 (t) (together 2H), 4.68 (t) and 4.80 (t) (together 2H), 7.28-7.40 (1H, m), 8.04 (2H, m), 8.22 (s) and 8.30 (s) (together 1H), m/z (API⁺): 207 (MH⁺; 80%).

15

Description 13**7-Amino-2-formyl-1,2,3,4-tetrahydroisoquinoline**

The compound D12 (2.3g) was dissolved in ethanol (50ml) and shaken at room temperature and 50psi with hydrogen in the presence of 5% Pd/C catalyst (0.8g). Filtration and evaporation then provided the title compound as a white solid (1.6g).

¹H NMR (250 MHz, d₆-DMSO) δ: 2.55(t) and 2.59(t) (together 2H), 3.56 (2H, t), 3.39 (s) and 3.41(s) (together 2H), 6.35-6.45 (2H, m), 6.79 (1H, d), 8.15 (s) and 8.18 (s) (together 1H), m/z(API⁺): 177 (MH⁺).

25

Description 14**2-(2-tert-Butyldimethylsilyloxyethyl)-7-nitro-1,2,3,4-tetrahydroisoquinoline**

7-Nitro-tetrahydroisoquinoline (5.0g; 28.0mmol) was dissolved in DMF (150ml). This solution was treated with (2-bromoethoxy)-tert-butyl-dimethylsilane (12.0ml; 56.0mmol), and stirred at 80°C overnight. The mixture was cooled to room temperature and the solvent removed *in vacuo*. Purification by column chromatography through SiO₂, eluting with 50% diethyl ether/petroleum ether gave the title compound (4.2g, 44%).

35

¹H NMR (250 MHz; CDCl₃) δ: 0.00 (6H, s), 0.83 (9H, s), 2.66 (2H, t, J = 6 Hz), 2.79 (2H, t, J = 6 Hz), 2.90 (2H, t, J = 6 Hz), 3.71 (2H, s), 3.77 (2H, t, J = 6 Hz), 7.16 (1H, d, J = 9 Hz), 7.82 (1H, d, J = 2 Hz), 7.89 (1H, dd, J = 9, 2 Hz).

5 **Description 15**

7-Amino-2-(2-*tert*-butyldimethylsilyloxyethyl)-1,2,3,4-tetrahydroisoquinoline

2-(2-*tert*-Butyldimethylsilyloxyethyl) compound D14 (2.88g; 8.57mmol) and 10% Pd/C (0.5g, 60% paste in water) in methanol (100ml) was hydrogenated in a manner similar to that of Description 5 to give the title compound (2.62g).

10

¹H NMR (250 MHz, CDCl₃) δ: 0.00 (6H, s), 0.83 (9H, s), 2.61 (2H, t, J = 6 Hz), 2.71 (4H, s, overlapping signals), 3.55 (2H, s), 3.77 (2H, t, J = 6 Hz), 6.27 (1H, d, J = 2 Hz), 6.43 (1H, d, J = 8 Hz), 6.80 (1H, d, J = 8 Hz).

15 **Description 16**

2-(2-*tert*-Butyldimethylsilyloxyethyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-bromo-4-ethoxybenzamide

Triethylamine (0.112ml; 0.81mmol) and 3-bromo-4-ethoxybenzoyl chloride (193mg; 0.73mmol) were dissolved in dichloromethane (100ml) with stirring. To this mixture was added the compound of D15 (204mg; 0.67mmol). The mixture was stirred overnight and then evaporated *in vacuo*. The resultant residue was purified by chromatography on silica with 10% methanol:dichloromethane to give the title compound (123mg; 35%).

20

25 ¹H NMR (250 MHz; CDCl₃) δ: 0.0 (6H, s), 0.82 (9H, s), 1.42 (3H, t, J = 7 Hz), 2.80 (2H, t, J = 5 Hz), 2.91 (2H, t, J = 5 Hz), 2.95 (2H, t, J = 4 Hz), 3.81 (2H, s), 3.87 (2H, t, J = 6 Hz), 4.08 (2H, q, J = 7 Hz), 6.84 (1H, d, J = 9 Hz), 7.00 (1H, d, J = 8 Hz), 7.29 (2H, d, J = 8 Hz), 7.33 (1H, s), 7.77 (1H, dd, J = 9, 2 Hz), 8.00 (1H, d, J = 2 Hz).

30

Description 17

7-Amino-2-(2-methoxyethyl)-1,2,3,4-tetrahydroisoquinoline

35 ¹H NMR (250 MHz; CDCl₃) δ: 2.74 (6H, m), 3.38 (3H, s), 3.60 (4H, m), 3.20 - 3.70 (2H, br), 6.37 (1H, s), 6.50 (1H, dd, J = 8, 2 Hz), 6.88 (1H, d, J = 8 Hz).

Description 18**5-Iodo-7-nitro-1,2,3,4-tetrahydroisoquinoline**

The nitro compound of Description 3 (750mg; 3.9mmol) and N-iodosuccinimide (1.13g) in triflic acid (5ml) was stirred at 25°C overnight. The mixture was poured cautiously into saturated NaHCO₃ and then extracted into ether (2x). The combined organic extracts were washed with aqueous sodium thiosulfate, dried (MgSO₄) and evaporation *in vacuo* gave a residue. Chromatography on Kieselgel 60 in 2% methanol - dichloromethane gave the title compound (650mg).

Description 19**7-Amino-5-iodo-1,2,3,4-tetrahydroisoquinoline**

A solution of the nitro compound D18 (650mg, 2.14mmol) in ethanol (20ml) at 50°C was treated with a solution of tin (II) chloride (1.42g) in c. HCl (3ml). The resultant yellow solution was basified with 10% aqueous sodium hydroxide and the product extracted into dichloromethane. Flash chromatography on Kieselgel 60 (5% methanol - dichloromethane) gave the title compound (428mg; 73%).

Description 20**7-Amino-5-iodo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline**

The iodoamine D19 (580mg, 2.12mmol) in DMF (30ml) was treated with DMAP (20mg) and di-*tert*-butyl-dicarbonate (466mg, 2.13mmol) and the solution was stirred at room temperature overnight. The reaction mixture was evaporated to dryness *in vacuo*. Chromatography on Kieselgel 60 (2% methanol - dichloromethane) gave the title compound (745mg; 94%).

Description 21**5,7-Dinitro-1,2,3,4-tetrahydroisoquinoline**

5-Nitro-1,2,3,4-tetrahydroisoquinoline (1.0g, 5.6mmol) in conc. sulfuric acid (3ml) was treated with conc. nitric acid (1ml) and the mixture stirred at room temperature for 1h. The mixture was cooled, basified with 40% aqueous NaOH and work-up with dichloromethane gave the title compound (1.14g).

Description 22**5,7-Dinitro-2-methyl-1,2,3,4-tetrahydroisoquinoline**

The amine D21 (1.8g) in formic acid (5ml) and paraformaldehyde (7ml) were reacted in a similar manner to that of Description 2 to give the title compound (1.74g, 91%).

^1H NMR (CDCl_3) δ : 2.51 (3H, s), 2.75 (2H, t), 3.27 (2H, t), 3.75 (2H, s), 8.16 (1H, d, J = 2Hz), 8.66 (1H, d, J = 2Hz); m/z (CI): 238.1 (MH^+ ; 100%).

Description 23

5 **5-Amino-7-nitro-2-methyl-1,2,3,4-tetrahydroisoquinoline**

The dinitro compound D22 (1.7g) was reduced with tin(II)chloride (5.42g) in a manner similar to that of Description 19 to give the title compound (0.6g).

Description 24

10 **5-Trifluoroacetylamino-7-nitro-2-methyl-1,2,3,4-tetrahydroisoquinoline**

The amine D23 (0.5g) in dichloromethane (10ml) and triethylamine (1.5eq) was treated with trifluoroacetic anhydride (1.1eq) and the mixture stirred at 25°C for 3h. Work-up with dichloromethane followed by chromatography on Kieselgel 60 in 3%-methanol:dichloromethane gave the title compound (0.7g, 96%).

15

m/z (CI): 304 (MH^+ ; 80%).

Description 25

7-Amino-5-trifluoroacetylamino-2-methyl-1,2,3,4-tetrahydroisoquinoline

20 The nitro compound D24 (0.7g, 2.28mmol) in ethanol (20ml) was hydrogenated over 10% Pd/C (70mg). The catalyst was removed by filtration through Celite and evaporation *in vacuo* gave the title compound as a pale solid (0.6g, 93%).

Description 26

25 **5-Chloro-7-nitro-2-methyl-1,2,3,4-tetrahydroisoquinoline**

The 5-amino compound D23 (1.6g, 7.7mmol) in 5M HCl (25ml) at 0°C was treated with a solution of sodium nitrite (0.55g, 8.0mmol) in water (3ml) over 5min. The cold solution was then added gradually to a solution of copper(I)chloride (1.0g, 10mmol) in 5M HCl (25ml). The mixture was stirred at 25°C for 30min and then basified with 40% NaOH. Work-up with dichloromethane (300ml) followed by flash chromatography on Kieselgel 60 (5% methanol:dichloromethane) gave the title compound (1.1g, 62%) as a yellow solid.

30

^1H NMR (CDCl_3) δ : 2.32 (3H, s), 2.61 (2H, t), 2.79 (2H, t), 3.57 (2H, s), 7.96 (1H, d, J = 2Hz), 8.08 (1H, d, J = 2Hz).

35

Description 27**7-Amino-5-chloro-2-methyl-1,2,3,4-tetrahydroisoquinoline**

The nitro D26 (0.80g, 3.5mmol) in ethanol (70ml) and conc. HCl (7ml) was heated to 50°C and tin(II)chloride (2.66g, 14mmol) was added. The mixture was heated for 15min and allowed to cool; work-up similar to that described in Description 19 gave the title compound as a yellow oil (0.48g).

^1H NMR (CDCl_3) δ : 2.42 (3H, s), 2.64 (2H, m), 2.77 (2H, m), 3.45(2H, d), 6.27 (1H, d, $J = 2\text{Hz}$), 6.59 (1H, d, $J = 2\text{Hz}$).

Preparation 1**3-Bromobenzyl TBMS ether**

To a solution of 3-bromobenzyl alcohol (5.00g, 0.027mole) in dichloromethane (30ml) and Et_3N (4.2ml, 0.03 mole) was added a 1M solution *tert*-butyldimethylsilyl chloride in dichloromethane (28.0ml) dropwise. The mixture was allowed to stir at room temperature overnight, then water (30ml) was added. The organic layer was washed with brine, dried (Na_2SO_4) and evaporated to give a red oil which was purified by flash chromatography on silica gel using 20% ether in hexane to give a colourless oil (8.0g).

Preparation 2**3-Pivaloylbenzylalcohol TBDMS Ether**

n-Butyllithium (2.80ml, 7.00mmol, 2.5M in hexane) was slowly added to a solution of Preparation 1 TBDMS ether (1.80g, 6.0mmol) in dry THF (10ml) over 5 min at -78°C. The reaction mixture was maintained under argon at -78°C for 1h. and *N,O*-dimethyl-hydroxy pivaloyl amide (0.86g, 6.60mmol) in THF (2ml) was added dropwise with stirring at -78°C. The resulting mixture was allowed to stir at -78°C for 2.5h, quenched with NH_4Cl solution and allowed to warm to room temperature. The mixture was extracted with ether (2x50ml), the combined organics were dried (Na_2SO_4) and concentrated *in vacuo* to give the title compound as a colourless oil (1.75g)

m/z (API^+): 307 (MH^+ ; 8%).

Preparation 3**3-Pivaloylbenzylalcohol**

The ether of Preparation 2 (1.47g, 4.80mmol) was dissolved in methanol (25ml); conc. HCl (20 drops) was added and the whole allowed to stir at room temperature for 4h. Saturated NaHCO_3 solution was added and the mixture extracted with ether (2x50ml).

The organic layer was dried over sodium sulfate and evaporation *in vacuo* gave title compound as a colourless oil (0.80g).

m/z (API⁺): 193 (MH⁺; 17%).

5

Preparation 4

3-Pivaloylbenzoic acid

3-Pivaloylbenzyl alcohol (0.80g, 4.16mmol) was dissolved in dioxane (20ml). A solution of KOH (0.35g, 6.30mmol) in water (5ml) was added followed by KMnO₄ (1.45g, 9.17 mmol). The mixture was stirred at room temperature over the weekend. The solution was filtered through Celite and extracted with ether. The aqueous phase was acidified with dil. HCl and extracted with ether (3x50ml). The organic layer was dried over magnesium sulphate and concentrated *in vacuo* to afford the title compound as a white solid (0.80g).

15

¹H NMR (250MHz, CDCl₃) δ : 1.38 (9H, s), 7.55 (1H, t), 7.92 (1H, d, J = 6.5Hz), 8.20 (1H, d, J = 6.5Hz), 8.44 (1H, s).

Preparation 5

3-Trifluoroacetylbenzoic acid

The title compound was prepared from diethyl trifluoroacetamide and 3-bromobenzyl TBDMS ether using a method similar to that described in Preparations 1, 2, 3 and 4.

m/z (API⁻): 217 (M-H⁺; 20%).

25

Preparation 6

Methyl 3-Chloro-4-*iso*-propoxybenzoate

Methyl 3-chloro-4-hydroxybenzoate (5g, 26.8mmol) in DMF (45ml) was treated with potassium carbonate (7.41g, 53.6mmol), 2-iodopropane (3.85ml, 40.2mmol) and then stirred at 25°C for 18h. Work-up with ethyl acetate gave the title compound (6.1g).

30

Preparation 7

3-Chloro-4-*iso*-propoxybenzoic acid

Methyl 3-chloro-4-*iso*-propoxybenzoate (5.5g, 24.1mmol) was hydrolysed using 1M NaOH (36ml) in methanol (80ml). Extraction and work-up with ethyl acetate gave the title compound (4.3g).

35

¹H NMR (DMSO-D₆) δ : 1.33 (6H, d), 4.79 (1H, m), 7.24 (1H, d), 7.87 (2H, m).

Preparation 8**3-Bromo-4-ethoxybenzoic acid**

The title compound was prepared from 4-ethoxybenzoic acid in a manner similar to that of Procedure 1.

¹H NMR (DMSO-D₆) δ: 1.45 (3H, t, J = 7 Hz), 4.26 (2H, q, J = 7 Hz), 7.26 (1H, d, J = 9 Hz), 7.98 (1H, dd, J = 2, 9 Hz), 8.12 (1H, d, J = 2 Hz)

Preparation 9**3-Bromo-4-ethylbenzoic acid**

The title compound was prepared from 4-ethylbenzoic acid.

¹H NMR (DMSO-D₆) δ: 1.20 (3H, t, J = 7 Hz), 2.78 (2H, q, J = 7 Hz), 7.50 (1H, d, J = 8 Hz), 7.90 (1H, dd, J = 2, 8 Hz), 8.07 (1H, d, J = 8 Hz)

Preparation 10**3-Cyano-4-*iso*-propylbenzoic acid**

The title compound was prepared from 4-*iso*-propylbenzoic acid similar to that described in Procedure 5.

¹H NMR (DMSO-D₆) δ: 1.07 (6H, d, J = 7 Hz), 3.13 (1H, m, overlapped), 7.48 (1H, d, J = 7 Hz), 7.96 (1H, dd, J = 2, 8 Hz), 8.00 (1H, d, J = 2 Hz).

Preparation 11**4-Methoxy-3-trifluoromethylbenzoic acid**

The title compound was prepared from 3-bromo-4-methoxybenzoic acid and potassium trifluoroacetate in a manner similar to that of Procedures 3 and 4.

¹H NMR (DMSO-D₆) δ: 3.78 (3H, s), 7.18 (1H, d, J = 9 Hz), 7.90 (1H, d, J = 2 Hz), 8.00 (1H, dd, J = 2, 9 Hz), 12.70 - 13.10 (1H, br, exchangeable)

Preparation 12**4-Methoxy-3-trifluoromethylbenzoyl chloride**

The title compound was prepared from 4-methoxy-3-trifluoromethylbenzoic acid with oxalyl chloride and DMF in chloroform at room temperature [D. Levin, Chem. Br., 1977, 20] followed by evaporation *in vacuo*.

Preparation 13**Methyl 3-Bromo-4-*iso*-propoxybenzoate**

5 Methyl 3-bromo-4-hydroxybenzoate (2.5g, 10.8mmol) in DMF (35ml) was treated with potassium carbonate (3.0g, 21.6mmol), 2-iodopropane (2.76, 21.6mmol) and then stirred at 25°C for 48h. Work-up with ethyl acetate gave the title compound (3.0g).

¹H NMR (250MHz, CDCl₃) δ: 1.41 (6H, d, J=7 Hz), 3.89 (3H, s), 4.66 (1H, m), 6.90 (1H, d, J = 8 Hz), 7.93 (1H, dd, J = 8, 2 Hz), 8.22 (1H, d, J = 2 Hz)

10

Preparation 14**Methyl 3-Cyano-4-*iso*-propoxybenzoate**

15 Methyl 3-bromo-4-*iso*-propoxybenzoate (2.0g, 7.3mmol) and copper(I)cyanide in N-methyl pyrrolidone (50ml) were heated under vigorous reflux for 4h. Work-up with ethyl acetate gave the title compound (1.0g).

¹H NMR (250MHz, CDCl₃) δ: 1.56 (6H, d, J=7 Hz), 4.05 (3H, s), 4.88 (1H, m), 7.13 (1H, d, J = 8 Hz), 8.31 (1H, dd, J = 8, 2 Hz), 8.38 (1H, d, J = 2 Hz)

20 **Preparation 15****Methyl 3,5 Dichloro-4-ethoxybenzoate**

The title compound was prepared in 69% yield from methyl 3,5-dichloro-4-hydroxybenzoic acid and iodoethane in a manner similar to that of Preparation 6.

25 ¹H NMR (250MHz, CDCl₃) δ: 1.47 (3H, t, J=7 Hz), 3.91 (3H, s), 4.16 (2H, q, J = 7 Hz), 7.96 (2H, s).

Preparation 16**3-Methanesulfonyl-4-*iso*-propylbenzoic acid**

30 3-Chlorosulfonyl-4-*iso*-propylbenzoic acid (2.62g, 10mmol) [made from 4-*iso*-propyl benzoic acid in a manner similar to that described in Procedures 7 and 8] was added slowly to a slurry of NaHCO₃ (2.52g, 30mmol) and Na₂SO₃ (1.26g 10mmol) in water (9ml) at 75°C. The mixture was stirred for 1h and then treated with bromoacetic acid (2.08g, 15mmol) and NaOH (0.60g, 15mmol). The temperature was raised to 105°C and
35 the mixture heated at reflux for 24h. The mixture was cooled, acidified to pH 1 and the resultant precipitate collected, washed and dried to give the title compound (1.43g, 59%).

¹H NMR (250MHz, acetone-D₆) δ: 1.24 (6H, d, J=7 Hz), 3.13 (3H, s), 3.88 (1H, m), 7.72 (1H, d, J = 7 Hz), 8.15 (1H, dd, J = 7 Hz), 8.52 (1H, d, J = 2 Hz).

Preparation 17

5 4-Methyl-3-methanesulfonylbenzoic acid

Prepared in 30% overall yield in a manner similar to that of Preparation 16.

¹H NMR (250MHz, acetone-D₆) δ: 2.57 (3H, s), 2.99 (3H, s), 7.39 (1H, d, J = 7 Hz), 7.97 (1H, dd, J = 7, 2 Hz), 8.39 (1H, d, J = 2 Hz).

10

Preparation 18

4-Ethyl-3-methanesulfonylbenzoic acid

Prepared in 44% overall yield in a manner similar to that of Preparation 16.

15 ¹H NMR (250MHz, acetone-D₆) δ: 1.22 (3H, t, J = 7 Hz), (3H, s), 3.05 (2H, q, J = 7 Hz), 3.12 (3H, s), 7.57 (1H, d, J = 7 Hz), 8.13 (1H, dd, J = 7, 2 Hz), 8.51 (1H, d, J = 2 Hz).

Preparation 19

3-Methanesulfonyl-4-methoxybenzoic acid

20 Prepared in 20% overall yield in a manner similar to that of Preparation 16.

¹H NMR (250MHz, acetone-D₆) δ: 3.00 (3H, s), 3.89 (3H, s), 7.17 (1H, d, J = 7 Hz), 8.06 (1H, dd, J = 7, 2 Hz), 8.31 (1H, d, J = 2 Hz).

25 Preparation 20

4-Ethoxy-3-methanesulfonylbenzoic acid

Prepared in 20% overall yield in a manner similar to that of Preparation 16.

30 ¹H NMR (250MHz, acetone-D₆) δ: 1.44 (3H, t, J = 7 Hz), (3H, s), 3.30 (3H, s), 4.35 (2H, q, J = 7 Hz), 7.40 (1H, d, J = 7 Hz), 8.20 (1H, dd, J = 7, 2 Hz), 8.37 (1H, d, J = 2 Hz).

Preparation 21

3-Chloro-4-ethoxybenzoic acid

35

¹H NMR (DMSO-D₆) δ: 1.39 (3H, t, J = 7 Hz), 4.20 (2H, q, J = 7 Hz), 7.22 (1H, d, J = 7 Hz), 7.87 (2H, m).

Preparation 22**4-*iso*-Propyloxy-3-trifluoromethylbenzoic acid**

Methyl 3-bromo-4-*iso*-propyloxybenzoate (828mg; 3.03 mmol) in DMF (25ml) was treated with potassium trifluoroacetate (922mg; 6.06 mmol), copper (I) iodide (1.15g; 6.06 mmol) and toluene (50ml). The resulting mixture was heated at reflux for 1.5h (Dean and Stark with removal of *ca* 50ml of distillate) followed by reflux for 18h then cooled. The mixture was poured into Et₂O (100ml) and H₂O (100ml). The two-phase mixture was stirred at room temperature for 0.5h then filtered through Celite. The two phases were separated, the aq. phase further extracted with Et₂O (50ml) and the organic extracts combined, washed with saturated, aq. Na₂S₂O₃, H₂O, saturated brine, dried (MgSO₄) and evaporated *in vacuo* to give a brown oil. This was dissolved in MeOH (*ca* 20ml) and treated with 2M NaOH (2ml; 4 mmol) and the resulting solution heated at reflux for 3h. The volatiles were removed *in vacuo* and the residue partitioned between EtOAc and H₂O. The phases were separated, the aq. phase acidified to pH1 with 2M HCl in the presence of EtOAc and the phases separated. The aq. phase was further extracted with EtOAc, the extracts combined, washed with H₂O, saturated brine, dried (MgSO₄) and evaporated to dryness *in vacuo* to give the title compound as a white solid (671mg; 89%).

¹H NMR (250MHz; (CD₃)₂CO) δ: 1.02 (6H, d, J = 6 Hz), 4.53 - 4.63 (1H, m), 7.01 (1H, d, J = 9 Hz), 7.85 - 7.88 (2H, m); ^{m/z} (API): 205.0 [M-Pr⁺].

Preparation 23**4-Ethyl-3-trifluoromethylbenzoic acid**

Prepared as described in Preparation 22 from methyl 4-ethyl-3-bromobenzoate (1.10g; 4.52 mmol) and isolated as a white solid (923mg; 93%).

¹H NMR (250MHz; (CD₃)₂CO) δ: 0.98 (3H, t, J = 7 Hz), 2.60 (2H, q, J = 7 Hz), 7.36 (1H, d, J = 8 Hz), 7.89 and 7.93 (1H, m), 7.96 (1H, br s); ^{m/z} (API): 217.1 [M-H].

Preparation 24**4-*n*-Propyloxy-3-trifluoromethylbenzoic acid**

Prepared as described in Preparation 22 from methyl 3-bromo-4-*n*-propyloxybenzoate (1.43g; 5.23 mmol) and isolated as a white solid (1.18g; 91%).

¹H NMR (250MHz; (CD₃)₂SO) δ: 1.09 (3H, t, J = 7 Hz), 1.79 - 1.93 (2H, m), 4.26 (2H, t, J = 6 Hz), 7.45 (1H, d, J = 9 Hz), 8.19 (1H, d, J = 2 Hz), 8.25 and 8.28 (1H, dd, J = 9, 2 Hz); ^{m/z} (API): 203.1 [M-CO₂H].

Preparation 25**4-*t*-Butyl-3-trifluoromethylbenzoic acid**

Prepared as described in Preparation 22 from methyl 3-bromo-4-*t*-butylbenzoate (2.46g; 9.1 mmol) and isolated as a white solid (1.55g; 69%).

5

¹H NMR (250MHz; (CD₃)₂SO) δ: 1.42 (9H, s), 7.86 - 7.90 (1H, m), 8.09 - 8.13 (1H, m), 8.23 (1H, d, J = 2 Hz); ^{m/z} (API): 245.1 [M-H].

Preparation 2610 **4-Oxochroman-6-carboxylic acid**

3-(4-Carboxyphenoxy)propionic acid (2.5g) [prepared according to the procedure of J. Lichtenberger and R. Geyer. Bull. Soc. Chim. Fr., 1963 275] in conc. sulfuric acid (20ml) was heated to 100°C for 4h and then poured onto crushed ice. The resultant precipitate was filtered and dried *in vacuo* to give the title compound (1.6g).

15

¹H NMR (DMSO-D₆) δ: 2.99 (2H, t, J = 7 Hz), 4.77 (2H, t, J = 7 Hz), 7.28 (1H, d, J = 8 Hz), 8.21 (1H, dd, J = 8, 2 Hz), 8.46 (1H, d, J = 2 Hz).

Preparation 2720 **3-Bromo-4-*iso*-propoxybenzoic acid**

The title compound was prepared using a method similar to that of Preparation 7.

¹H NMR (DMSO-D₆) δ: 1.29 (6H, d, J = 7 Hz), 4.77 (1H, sep, J = 7 Hz), 7.20 (1H, d, J = 8 Hz), 7.87 (1H, dd, J = 8, 2 Hz), 8.02 (1H, d, J = 2 Hz), 12.92 (1H, brs).

25

Preparation 28**4-Azidobenzoic acid**

To a solution of 4-aminobenzoic acid (2.00g, 14.00mmol) in trifluoroacetic acid (10ml) at 5°C, was added sodium nitrite (3.50g) portionwise, and the mixture allowed to stir for 30 min. Sodium azide (3.79g,) was then added portionwise and the mixture stirred for a further 30 min at 0°C. The mixture was diluted with water, and a white solid precipitated. The solid was filtered, washed with cold water and dried, to afford the title compound (1.66g, 73%).

35 **Procedure 1****5-Bromo-2,4-dimethoxybenzoic acid**

To a solution of 2,4-dimethoxybenzoic acid (4.0g, 0.022mol) in chloroform (60ml) was added bromine (1.13ml, 0.022mol) in chloroform (20ml) dropwise. After stirring overnight

at room temperature the precipitate was filtered off and dried to afford the title compound as a white solid (2.87g).

Procedure 2

5 5-Bromo-4-*iso*-propyl-2-methoxybenzoic acid

To a solution of 2-methoxy-4-*iso*-propyl benzoic acid (7.0g, 36.0 mmol) in chloroform (100 ml) was added bromine (1.86 ml) in chloroform (20 ml) dropwise. The reaction was stirred at room temperature overnight. Evaporation *in vacuo* afforded an oil (9.27g).

10 m/z (CI): 275, 273 (MH^+ ; 70%).

Procedure 3

Methyl 5-bromo-4-*iso*-propyl-2-methoxy benzoate

15 5-Bromo-4-*iso*-propyl-2-methoxybenzoic acid (9.268g 34.0 mmol) was dissolved in methanol (250 ml) and conc. H_2SO_4 (2 ml) added. The mixture was refluxed for 5h and concentrated *in vacuo*. Residual material was taken up into ethyl acetate and water, and the organic layer, dried ($MgSO_4$). Concentration *in vacuo* afforded an oil, which was purified by Biotage Column Chromatography on silica gel using 10% ether in hexane to give an oil (5.5g).

20

Procedure 4

2,4-Dimethoxy-5-trifluoromethylbenzoic acid

2,4-Dimethoxy-5-bromobenzoic acid methyl ester (1.5g; 5.4 mmol) in DMF (25ml) and toluene (8ml) under argon was treated with potassium trifluoroacetate (1.53g; 10.1 mmol) and copper (I) iodide (2.1g, 10.9 mmol). The mixture was heated to 170°C with removal of water (Dean/Stark), and then at 155°C overnight. The mixture was allowed to cool, poured into ether and water and filtered through Kieselguhr. The organic layer was dried (Na_2SO_4) and concentrated *in vacuo* to give a brown solid. Chromatography on Kieselgel 60 with 1:1 ether/petrol gave a solid (1.03g) which was hydrolysed in 1:1 methanolic: aqueous NaOH (50ml) at 50°C. Work-up gave the title compound as a white solid (1g).

30

Procedure 5a

Methyl 2-methoxy-5-cyano-4-*iso*-propylbenzoate

35 Copper (I) cyanide (550mg, 6mmol) was added to a solution of methyl 2-methoxy-5-bromo-4-*iso*-propylbenzoate (861mg) in N-methyl-2-pyrrolidinone (30ml). The mixture was stirred under argon and boiled under reflux for 4h. The mixture was cooled, poured into excess ice/water and ethyl acetate and filtered. The organic phase was separated, washed with water, brine and dried ($MgSO_4$). Evaporation gave a crude brown solid

which was purified by chromatography on silica gel eluting with ethyl acetate/n-hexane (1:4). The product was obtained as a white solid (523 mg).

¹H NMR (250MHz, CDCl₃) δ: 1.33 (6H, d, J=7Hz), 3.38 (1H, sep, J=7Hz), 3.89 (3H, s),
5 3.98 (3H, s), 6.91 (1H, s), 8.08 (1H, s); m/z (API⁺): 234 (MH⁺, 30%).

Procedure 5b

2-Methoxy-5-cyano-4-*iso*-propylbenzoic acid

2N NaOH (1.25ml) was added to a solution of the methyl ester P5a (490mg) in methanol
10 (10ml). The solution was stirred overnight at room temperature. The solution was then diluted with water, concentrated *in vacuo* and washed with ethyl acetate. The aqueous phase was then acidified with 2N HCl and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO₄) and evaporated to dryness giving the product as a white solid (418mg).

15 ¹H NMR (250MHz, CDCl₃) δ: 1.35 (6H, d, J=7Hz), 3.43 (1H, sep, J=7Hz), 4.14 (3H,s), 7.00 (1H, s), 8.41 (1H, s); m/z (API⁺): 220 (MH⁺, 100%).

Procedure 6a

Ethyl 2-ethoxy-4-*iso*-propyl-5-cyanobenzoate

20 Ethyl 2-ethoxy-4-*iso*-propyl-5-bromobenzoate (1.2g, 3.8mmol) was treated with copper (I) cyanide (682mg, 7.6 m.mol) in N-methyl-2-pyrrolidinone (40ml) as described in Procedure 5 to give the title compound as an oil (400mg).

¹H NMR (250MHz, CDCl₃) δ: 1.12 (6H, d, J=7Hz), 1.30 (3H, t, J=7Hz), 1.84 (3H, t, J=7Hz), 3.17 (1H, sep, J=7Hz), 3.99 (2H, q, J=9Hz), 4.16 (2H, q, J=7Hz), 6.69 (1H, s),
25 7.86 (1H, s); m/z (API⁺): 262 (MH⁺, 100%).

Procedure 6b

2-Ethoxy-4-*iso*-propyl-5-cyanobenzoic acid

30 The ester P6a (370mg, 1.41mmol) was dissolved in methanol (5ml) and over a 24 h period 1N NaOH (2.1ml, 2.1mmol) was added. The solution was concentrated under vacuum, diluted with water and washed with ethyl acetate. The aqueous phase was acidified with 2N HCl and extracted with ethyl acetate. The extract was washed with brine, dried (Mg SO₄) and evaporated to give the title acid (306 mg).

35

¹H NMR (250MHz CDCl₃) δ: 1.39 (3H, d, J=7Hz), 1.66 (3H, t, J=7Hz), 3.47 (1H, sep, J=7Hz), 4.46 (2H, q, J=7Hz), 7.03 (1H, s), 8.47 (1H, s); m/z (API⁺): 234 (MH⁺, 100%).

Procedure 7**4-Ethoxy-2-methoxy-5-methylsulfonylbenzoic acid**

- 4-Ethoxy-2-methoxy-5-chlorosulfonyl benzoic acid was prepared in 49% yield using the procedure of M.W. Harrold *et al.*, J. Med. Chem., 1989, **32** 874. This was used according to the method of R.W. Brown, J. Org. Chem., 1991, **56**, 4974, to the title compound in 19% yield.

¹H NMR (DMSO-D₆) δ: 1.30 (3H, t), 3.10 (3H, s), 3.83 (3H, s), 4.24 (2H, q), 6.73 (1H, s), 8.07 (1H, s).

10

Procedure 8**4-iso-Propyl-2-methoxy-5-methylsulfonylbenzoic acid**

- This was prepared in a similar manner to the procedure of C. Hansch, B. Schmidhalter, F. Reiter, W. Saltonstall. J. Org. Chem., 1956, **21**, 265 to afford the intermediate 5-chlorosulfonyl-4-isopropyl-2-methoxybenzoic acid which was converted into the title compound using the method of Procedure 7.

15

¹H NMR (DMSO-D₆) δ: 1.30 (6H, d), 3.21 (3H, s), 3.80 (1H, m), 3.94 (3H, s), 7.26 (1H, s), 8.19 (1H, s).

20

Example 1**N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide, monotrifluoroacetate**

- The N-boc amine D7 (0.48g; 1.22 mmol) in dichloromethane (25ml) containing trifluoroacetic acid (2ml) was kept at 25°C for 18h. Evaporation *in vacuo* followed by crystallisation of the residue from ethyl acetate - ether gave the title compound as off-white crystals (0.46g; 92%), m.p. 153-5°C.
- ¹H NMR (400MHz, DMSO-d₆)δ: 2.96 (2H, t), 3.38 (2H, t), 4.29 (2H, s), 7.23 (1H, d), 7.28 (1H, d, ABq), 7.51 (1H, dd), 7.63 (1H, d), 7.90 (1H, d, ABq), 9.01 (2H, br, s), 10.33 (1H, s); m/z (CI): 293 (MH⁺; 100%).

30

Example 2

- N-(2-Methyl-tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide**

35

The compound of Example 1 (200mg; 0.5 mmol), 98% formic acid (0.4ml) and aqueous formaldehyde (0.6ml) were treated according to the procedure of Description 4.

Chromatography on Kieselgel 60 in methanol - ethyl acetate followed by crystallisation from ethyl acetate - ether gave the title compound as an off-white powder, m.p. 138-40°C.

- 5 ^1H NMR (250MHz, CDCl_3) δ : 2.46 (3H, s), 2.69 (2H, t), 2.89 (2H, t), 3.54 (2H, s), 6.93 and 7.37 (2H, ABq), 7.07 (1H, d), 7.25 (1H, dd), 7.34 (1H, d), 7.63 (1H, br, s); m/z (CI): 307 (MH^+ ; 100%).

Example 3

- 10 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzamide**

The N-methyl amine D5 in dichloromethane (25ml) containing triethylamine (0.5ml) was treated with benzoyl chloride and the mixture kept at 25°C for 18h. Normal work-up gave the product which was chromatographed on Kieselgel 60 by gradient elution in ethyl acetate:hexane. Combination of appropriate fractions gave the title compound.

^1H NMR (250MHz, CDCl_3) δ : 2.46 (3H, s), 2.69 (2H, t), 2.91 (2H, t), 3.58 (2H, s), 7.10 (1H, d), 7.30 (1H, dd), 7.40 - 7.60 (4H, overlapping m), 7.75 (1H, br s), 7.87 (2H, m).

- 20 *The following Examples were made using procedures similar to the methods described earlier.*

Example 4

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chlorobenzamide

25

^1H NMR (250MHz, CDCl_3) δ : 2.46 (3H, s), 2.68 (2H, t), 2.90 (2H, t), 3.57 (2H, s), 7.10 (1H, d), 7.29 (1H, dd, overlapping with CHCl_3), 7.39 (1H, s), 7.42 (1H, d), 7.52 (1H, m), 7.73 (1H, m), 7.83 (2H, m).

- 30 **Example 5**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*t*-butylbenzamide

- 35 ^1H NMR (250MHz, CDCl_3) δ : 1.34 (9H, s), 2.44 (3H, s), 2.68 (2H, t), 2.89 (2H, t), 3.55 (2H, s), 7.07 (1H, d), 7.29 (1H, dd overlapping with CHCl_3 signal), 7.38 - 7.53 (3H, m, overlapping signals), 7.75 - 7.90 (3H, m, overlapping signals).

Example 6**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxybenzamide**

5 ^1H NMR (250MHz, CDCl_3) δ : 1.38 (6H, d), 2.46 (3H, s), 2.69 (2H, t), 2.90 (2H, t), 3.58 (2H, s), 4.64 (1H, septet), 6.94 (2H, m), 7.09 (1H, d), 7.23 - 7.34 (1H, m, overlapping CHCl_3), 7.42 (1H, s), 7.70 (1H, br s), 7.81 (2H, m); m/z (CI): 325 (MH^+ , 100%).

Example 7**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenoxybenzamide**

10

^1H NMR (250MHz, CDCl_3) δ : 2.46 (3H, s), 2.69 (2H, t), 2.91 (2H, t), 3.59 (2H, s), 7.00 - 7.50 (10H, overlapping m), 7.72 (1H, br s), 7.83 (2H, m).

Example 815 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-nitrobenzamide**

^1H NMR (CDCl_3) δ : 2.45 (3H, s), 2.70 (2H, m), 2.90 (2H, m), 3.60 (2H, s), 7.10 (2H, dd), 7.25 (1H, dd), 7.40 (1H, d), 8.00 (2H, dd), 8.35 (2H, dd), 7.80 (1H, s).
 m/z (CI): 312 (MH^+ , 70%).

20

Example 9**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenylbenzamide**

25 ^1H NMR (CDCl_3) δ : 2.45 (3H, s), 2.70 (2H, m), 2.90 (2H, m), 3.60 (2H, s), 6.30 (1H, d), 6.50 (1H, dd), 6.90 (1H, dd), 7.10 (1H, d), 7.40 (2H, m), 7.60 (1H, dd), 7.70 (1H, dd), 7.80 (1H, s), 7.90 (1H, d), 8.05 (1H, s); m/z (CI): 343 (MH^+ ; 90%).

Example 10**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylbenzamide**

30

^1H NMR (CDCl_3) δ : 2.43 (3H, s), 2.47 (3H, s), 2.70 (2H, t), 2.90 (2H, t), 3.60 (2H, s), 7.05 (1H, dd), 7.30 (1H, m), 7.35 (2H, m), 7.45 (1H, s), 7.65 (3H, m).
 m/z (CI): 281 (MH^+ ; 90%).

Example 11**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluorobenzamide**

¹H NMR (CDCl₃)δ: 2.50 (3H, s), 2.75 (2H, t), 2.90 (2H, t), 3.65 (2H, s), 7.10 (1H, dd),
5 7.28 (2H, m), 7.40 (2H, m), 7.60 (2H, m), 7.75 (1H, s); m/z (CI): 285 (MH⁺; 100%).

Example 12**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyanobenzamide**

10 ¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.70 (2H, t), 2.90 (2H, t), 3.60 (2H, s), 7.12 (1H, dd),
7.30 (1H, m), 7.40 (1H, s), 7.65 (1H, dt), 7.80 (2H, m), 8.10 (1H, d), 8.15 (1H, s).
m/z (CI): 292 (MH⁺).

Example 13**15 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dichlorobenzamide**

¹H NMR (CDCl₃)δ: 2.50 (3H, s), 2.80 (2H, t), 2.90 (2H, t), 3.70 (2H, s), 7.10 (1H, d),
7.30 (1H, dd), 7.40 (1H, s), 7.55 (1H, d), 7.70 (1H, dd), 8.00 (2H, m).
m/z (CI): 335 (MH⁺).

20

Example 14**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-iodobenzamide**

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.71 (2H, t), 2.89 (2H, t), 3.58 (2H, s), 7.10 (1H, d),
25 7.30 (1H, m), 7.43 (1H, s), 7.60 and 7.85 (4H, ABq), 7.82 (1H, s).
m/z (CI): 393 (MH⁺; 100%).

Example 15**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-bromobenzamide**

30

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.71 (2H, t), 2.89 (2H, t), 3.60 (2H, s), 7.10 (1H, d),
7.30 (1H, m), 7.43 (1H, s), 7.64 and 7.74 (4H, ABq), 7.70 (1H, s).
m/z (CI): 347, 345 (MH⁺; 100%).

Example 16**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methylbenzamide**

¹H NMR (CDCl₃)δ: 2.44 (3H, s), 2.48 (3H, s), 2.75 (2H, t), 2.90 (2H, t), 3.63 (2H, s),
5 7.10 (1H, d), 7.28 and 7.78 (4H, ABq), 7.30 (1H, m), 7.44 (1H, s), 7.74 (1H, m).
m/z (CI): 281.2 (MH⁺; 100%).

Example 17**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-nitrobenzamide**

10

¹H NMR (CDCl₃)δ: 2.48 (3H, s), 2.71 (2H, t), 2.92 (2H, t), 3.61 (2H, s), 7.13 (1H, d),
7.34 (1H, dd), 7.42 (1H, s), 7.71 (1H, t), 8.00 (1H, d), 8.26 (1H, d), 8.40 (1H, d), 8.70
(1H, t); m/z (CI): 312.1 (MH⁺; 100%).

15 **Example 18****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide**

¹H NMR (CDCl₃)δ: 1.46 (3H, m), 2.47 (3H, s), 2.71 (2H, t), 2.90 (2H, t), 3.61 (2H, s),
4.11 (2H, m), 7.14 (1H, d), 7.30 (1H, m), 7.49 (1H, s), 7.68 (1H, s), 7.82 (2H, d), 8.10
20 (3H, m); m/z (CI): 311.2 (MH⁺; 100%).

Example 19**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-butylbenzamide**

¹H NMR (CDCl₃)δ: 0.93 (3H, t), 1.25 - 1.48 (2H, m), 1.52 - 1.70 (2H, m), 2.51 (3H, s),
2.66 (2H, m), 2.80 (2H, t), 2.95 (2H, t), 3.69 (2H, s), 7.12 (1H, d), 7.20 (1H, d), 7.29
(2H, d), 7.32 (1H, m), 7.47 (1H, s), 7.78 (2H, d), 7.93 (1H, d); m/z (CI): 323.2 (MH⁺;
100%).

30 **Example 20****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-acetoxymethylbenzamide**

¹H NMR (CDCl₃)δ: 2.33 (3H, s), 2.48 (3H, s), 2.71 (2H, t), 2.91 (2H, t), 3.61 (2H, s),
7.10 (1H, d), 7.16 (1H, d), 7.23 (1H, m), 7.32 - 7.45 (2H, m), 7.52 (1H, t), 7.83 (1H, d),
35 7.94 (1H, s); m/z (CI): 325.2 (MH⁺; 100%).

Example 21**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoromethylbenzamide**

¹H NMR (CDCl₃)δ: 2.48 (3H, s), 2.73 (2H, t), 2.92 (2H, t), 3.62 (2H, s), 7.11 (1H, d),
5 7.32 (1H, d), 7.42 (1H, s), 7.63 (1H, t), 7.75 - 7.91 (2H, m), 8.07 (1H, t), 8.12 (1H, s).
m/z (CI): 335.1 (MH⁺; 100%)

Example 22**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-difluorobenzamide**

10

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.71 (2H, t), 2.92 (2H, t), 3.61 (2H, s), 6.95 (1H, m),
7.00 - 7.18 (2H, m), 7.32 (1H, dd), 7.44 (1H, s), 8.14 - 8.36 (2H, m).
m/z (CI): 303.1 (MH⁺; 100%).

15 **Example 23****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dimethoxybenzamide**

m/z (CI): 327.2 (MH⁺; 100%).

20 **Example 24****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-fluoro-4-trifluoromethyl benzamide**

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.70 (2H, t), 2.92 (2H, t), 3.61 (2H, s), 7.11 (1H, d),
25 7.35 (1H, dd), 7.45 (2H, s), 7.50 (1H, s), 7.59 (1H, d), 8.20 - 8.40 (2H, br m).
m/z (CI): 353.1 (MH⁺; 100%).

Example 25**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-nitrobenzamide**

30

¹H NMR (CDCl₃)δ: 2.48 (3H, s), 2.72 (2H, t), 2.94 (2H, t), 3.60 (2H, s), 7.10 (1H, d),
7.32 (1H, d), 7.38 (1H, s), 7.67 (1H, d), 7.95 - 8.13 (2H, br m), 8.38 (1H, d).
m/z (CI): 348 (MH⁺; 33%), 346.1 (MH⁺; 100%).

Example 26**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-di-trifluoromethylbenzamide**

¹H NMR (CDCl₃)δ: 2.52 (3H, s), 2.78 (2H, t), 2.94 (2H, t), 3.66 (2H, s), 7.14 (1H, d),
5 7.36 (1H, d), 7.42 (1H, s), 7.94 (1H, m), 8.04 (1H, s), 8.32 (2H, s).
m/z (CI): 403.1 (MH⁺; 100%).

Example 27**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-dichloro-5-fluorobenzamide**

10

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.70 (2H, t), 2.91 (2H, t), 3.60 (2H, s), 7.11 (1H, d),
7.25 (1H, d), 7.38 (1H, s), 7.52 (1H, dd), 7.62 (1H, dd), 7.90 (1H, brs).
m/z (CI): 353.0 (MH⁺; 100%).

15 **Example 28****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-5-trifluoromethylbenzamide**

¹H NMR (CDCl₃)δ: 2.49 (3H, s), 2.73 (2H, t), 2.91 (2H, t), 3.62 (2H, s), 7.13 (1H, d),
20 7.32 (1H, dd), 7.40 (1H, s), 7.50 (1H, d), 7.80 (1H, m), 7.90 (1H, s), 8.02 (1H, s).
m/z (CI): 353.1 (MH⁺; 100%).

Example 29**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide**

25

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.71 (2H, t), 2.91 (2H, t), 3.60 (2H, s), 3.97 (3H, s),
6.96 (1H, d), 7.10 (1H, d), 7.29 (1H, m), 7.40 (1H, s), 7.67 (1H, s), 7.84 (1H, dd), 8.02
(1H, s), 8.05 (1H, d); m/z (CI): 377, 375 (MH⁺; 30%).

30 **Example 30****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4,5-trimethoxybenzamide**

¹H NMR (CDCl₃)δ: 2.42 (3H, s), 2.66 (2H, t), 2.88 (2H, t), 3.55 (2H, s), 3.83 (3H, s),
3.86 (6H, s), 7.00 (1H, s), 7.05 (1H, d), 7.19 (1H, s), 7.26 (1H, d), 7.34 (1H, s), 7.68
35 (1H, s), 7.94 (1H, s); m/z (CI): 357.2 (MH⁺; 100%).

Example 31**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethoxybenzamide**

¹H NMR (CDCl₃)δ: 2.47 (3H, s), 2.70 (2H, t), 2.91 (2H, t), 3.60 (2H, s), 7.10 (1H, d),
5 7.25 (1H, m), 7.32 (2H, d), 7.40 (1H, s), 7.74 (1H, s), 7.90 (2H, d);
m/z (CI): 351.1 (MH⁺; 100%).

Example 32

10 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-pivaloylbenzamide,
hydrochloride**

The acid of Preparation 5 (200mg, 1.0mmol) and oxalyl chloride (140mg, 1.1mmol) in
dichloromethane (10ml) containing DMF (5 drops) was stirred at 25°C for 1h and then
evaporated to dryness *in vacuo*. The residue in dichloromethane was treated with the
15 amine D5 (162mg, 1.0mmol) and kept at 25°C overnight. Work-up similar to that of
Example 2 gave the title compound (110mg), m.p. 197 - 201°C (from methanol:ether).

¹H NMR (free base; 250 MHz; CDCl₃)δ: 1.38 (9H, s), 2.45 (3H, s), 2.68 (2H, t), 2.89
(2H, t), 3.55 (2H, s), 7.08 (1H, d), 7.30 (1H, d), 7.40 (1H, s), 7.49 (1H, t), 7.83 (1H, d),
20 7.95 (1H, d), 8.08 (1H, s), 8.14 (1H, s); m/z (CI): 351.2 (MH⁺; 100%).

Example 33**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-iso-propoxybenzamide**

25 ¹H NMR (CDCl₃) δ: 1.42 (6H, d, J = 6 Hz), 2.47 (3H, s), 2.71 (2H, t, J = 6 Hz), 2.91
(2H, t, J = 6 Hz), 3.60 (2H, s), 4.67 (1H, dt, J = 6 Hz), 6.96 (1H, d, J = 9 Hz), 7.10 (1H,
d, J = 8 Hz), 7.30 (1H, m), 7.40 (1H, d, J = 2 Hz), 7.71 (1H, s), 7.80 (1H, dd, J = 2 and 9
Hz), 8.05 (1H, d, J = 2 Hz).

30 **Example 34**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-acetoxybenzamide

¹H NMR (CDCl₃) δ: 2.34 (3H, s), 2.48 (3H, s), 2.73 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6
HZ), 3.62 (2H, s), 7.11 (1H, d, J = 8 Hz), 7.21 (2H, m), 7.31 (1H, m), 7.43 (1H, s), 7.75
35 (1H, s), 7.88 (2H, m); m/z (CI): 325 (MH⁺; 100%)

Example 35**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopentyloxybenzamide**

5 ^1H NMR (CDCl_3) δ : 1.56 - 1.68 (2H, bm), 1.74 - 1.97 (6H, bm), 2.61 (3H, s), 2.95 (4H, m), 3.79 (2H, s), 4.81 (1H, m), 6.38 (1H, s), 6.54 (1H, dd, $J = 2$ and 8 Hz), 6.85 (2H, m), 6.93 (2H, d, $J = 8$ Hz), 7.95 (2H, d, $J = 8$ Hz); m/z (CI): 349 (MH^+ ; 20%)

Example 36**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopropylmethoxybenzamide**

10 ^1H NMR (CDCl_3) δ : 0.36 (2H, m), 0.66 (2H, m), 1.28 (1H, m), 2.44 (3H, s), 2.81 (2H, t, $J = 6$ Hz), 2.89 (2H, t, $J = 6$ Hz), 3.51 (2H, s), 3.86 (2H, m), 6.34 (1H, d, $J = 2$ Hz), 6.50 (1H, dd, $J = 2$ and 8 Hz), 6.92 (2H, m), 7.06 (1H, d, $J = 8$ Hz), 7.31 (1H, dd, $J = 2$ and 8 Hz), 7.82 (1H, m), 8.00 (1H, m); m/z (CI): 337 (MH^+ ; 100%).

15

Example 37**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-methoxybenzamide**

20 ^1H NMR (CDCl_3) δ : 2.47 (3H, s), 2.70 (2H, t, $J = 6$ Hz), 2.91 (2H, t, $J = 6$ Hz), 3.59 (2H, s), 4.02 (3H, s), 7.09 (2H, t, $J = 8$ Hz), 7.29 (1H, dd, $J = 2$ and 8 Hz), 7.39 (1H, d, $J = 2$ Hz), 7.80 (1H, s), 8.10 (2H, m); m/z (CI): 322 (MH^+ ; 100%)

Example 38**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-naphthamide**

25

^1H NMR (CDCl_3) δ : 2.50 (3H, s), 2.75 (2H, t, $J = 6$ Hz), 2.94 (2H, t, $J = 6$ Hz), 3.65 (2H, s), 7.13 (1H, d, $J = 8$ Hz), 7.38 (1H, dd, $J = 2$ and 8 Hz), 7.50 (1H, d, $J = 2$ Hz), 7.56 - 7.22 (3H, bm), 7.88 - 8.07 (4H, bm), 8.38 (1H, s); m/z (CI): 317 (MH^+ ; 100%)

Example 39**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide**

30 ^1H NMR (CDCl_3) δ : 2.47 (6H, bs), 2.71 (2H, t, $J = 6$ Hz), 2.91 (2H, t, $J = 6$ Hz), 3.60 (2H, s), 7.10 (1H, d, $J = 8$ Hz), 7.23 - 7.39 (2H, bm), 7.42 (1H, s), 7.70 (2H, dd, $J = 2$ and 8 Hz), 8.02 (1H, d, $J = 2$ Hz); m/z (CI): 359, 361 (MH^+ ; 100%)

35

Example 40**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-naphthalene-1-carboxamide**

5 ^1H NMR (CDCl_3) δ : 2.50 (3H, s), 2.75 (2H, t, $J = 6$ Hz), 2.92 (2H, t, $J = 6$ Hz), 3.66 (2H, s), 7.12 (1H, d, $J = 8$ Hz), 7.35 (1H, d, $J = 8$ Hz), 7.45 - 7.70 (5H, m), 7.75 (1H, d, $J = 8$ Hz), 7.90 (1H, m), 7.96 (1H, d, $J = 7$ Hz), 8.36 (1H, d, $J = 8$ Hz).
 m/z (API^+): 317.2 (MH^+ ; 100%).

Example 4110 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-methoxybenzamide**

^1H NMR (CDCl_3) δ : 2.47 (3H, s), 2.70 (2H, t, $J = 6$ Hz), 2.91 (2H, t, $J = 6$ Hz), 3.59 (2H, s), 3.97 (3H, s), 6.99 (1H, d, $J = 9$ Hz), 7.09 (1H, d, $J = 8$ Hz), 7.32 (1H, dd, $J = 2$ and 8 Hz), 7.40 (1H, s), 7.79 (2H, m), 7.90 (1H, d, $J = 2$ Hz).

15

Example 42**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*tert*-butoxybenzamide**

20 ^1H NMR (CDCl_3) δ : 1.41 (9H, s), 2.47 (3H, s), 2.71 (2H, t, $J = 6$ Hz), 2.91 (2H, t, $J = 6$ Hz), 3.61 (2H, s), 7.03 - 7.12 (3H, b m), 7.30 (1H, dd, $J = 2$ and 8 Hz), 7.43 (1H, d, $J = 2$ Hz), 7.68 (1H, s), 7.79 (2H, d, $J = 9$ Hz); m/z (CI): 339 (MH^+ ; 100%).

Example 43**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxybenzamide**

25

^1H NMR (CDCl_3) δ : 1.01 (3H, t, $J = 7$ Hz), 1.83 (2H, m), 2.87 (3H, s), 3.19 (2H, m), 3.44 (2H, t, $J = 7$ Hz), 3.61 (2H, s), 3.87 (2H, m), 4.40 (2H, s), 6.93 (2H, d), 7.09 (1H, d), 7.51 (1H, dd, $J = 8, 2$ Hz), 7.61 (1H, d), 7.92 (2H, d), 8.39 (1H, s).

30 **Example 44****N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl) benzotriazole-5-carboxamide**

m/z (CI): 308 (MH^+ ; 65%)

Example 45**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzothiazole-6-carboxamide**

¹H NMR (CDCl₃) δ: 2.48 (3H, s), 2.72 (2H, t, J = 6 Hz), 2.93 (2H, t, J = 6 Hz), 3.62 (2H, s), 7.13 (1H, d, J = 8 Hz), 7.34 (1H, dd, J = 2 and 8 Hz), 7.45 (1H, d, J = 2 Hz), 7.88 (1H, s), 7.97 (1H, dd, J = 2 and 8 Hz), 8.22 (1H, d, J = 8 Hz), 8.56 (1H, d, J = 2 Hz), 9.15 (1H, s); m/z (CI): 322 (MH⁺: 100%)

Example 46**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,3-dihydrobenzofuran-5-carboxamide**

¹H NMR (CDCl₃) δ: 2.48 (3H, s), 2.73 (2H, t, J = 6 Hz), 2.91 (2H, t, J = 6 Hz), 3.27 (2H, t, J = 9 Hz), 3.62 (2H, s), 4.66 (2H, t, J = 9 Hz), 6.83 (1H, d, J = 8 Hz), 7.08 (1H, d, J = 8 Hz), 7.28 (1H, dd, J = 2 and 8 Hz), 7.42 (1H, s), 7.64 (1H, d, J = 8 Hz), 7.76 (2H, m). m/z (CI): 309 (MH⁺; 100%).

Example 47**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylbenzimidazole-5-carboxamide**

¹H NMR (d₄MeOH) δ: 2.51 (3H, s), 2.61 (3H, s), 2.92 (2H, t, J = 6 Hz), 2.96 (2H, t, J = 6 Hz), 3.69 (2H, s), 7.14 (1H, d, J = 9 Hz), 7.47 (3H, m), 7.56 (1H, d, J = 8 Hz), 7.80 (1H, dd, J = 2 and 8 Hz), 8.10 (1H, s); m/z (CI): 321 (MH⁺; 100%).

Example 48**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide**

¹H NMR (CDCl₃) δ: 1.42 (6H, d, J = 6 Hz), 2.49 (3H, s), 2.74 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.63 (2H, s), 4.67 (1H, quintet, J = 6 Hz), 6.98 (1H, d, J = 9 Hz), 7.09 (1H, d, J = 8 Hz), 7.28 (1H, dd, J = 2 and 8 Hz), 7.40 (1H, d, J = 2 Hz), 7.67 - 7.81 (2H, bm), 7.88 (1H, d, J = 2 Hz); m/z (CI): 359 (MH⁺; 100%).

Example 49**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide**

¹H NMR (CDCl₃) δ: 1.51 (3H, t, J = 7 Hz), 2.49 (3H, s), 2.74 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.62 (2H, s), 4.17 (2H, q, J = 7 Hz), 6.93 (1H, d, J = 9 Hz), 7.09 (1H, d,

J = 8 Hz), 7.28 (1H, dd, J = 2 and 8 Hz), 7.39 (1H, d, J = 2 Hz), 7.71 (1H, s), 7.80 (1H, dd, J = 2 and 9 Hz), 8.05 (1H, d, J = 2 Hz); m/z (CI): 389, 391 (MH⁺; 100%)

Example 50

5 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-ethoxybenzamide**

¹H NMR (CDCl₃) δ: 1.51 (3H, t, J = 7 Hz), 2.49 (3H, s), 2.74 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.62 (2H, s), 4.18 (2H, q, J = 7 Hz), 6.96 (1H, d, J = 9 Hz), 7.09 (1H, d, J = 8 Hz), 7.31 (1H, dd, J = 2 and 8 Hz), 7.39 (1H, d, J = 2 Hz), 7.76 (2H, m), 7.89 (1H, d, J = 2 Hz); m/z (CI): 345 (MH⁺; 100%).

Example 51

15 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl benzamide**

¹H NMR (CDCl₃) δ: 2.48 (3H, s), 2.72 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.60 (2H, s), 3.98 (3H, s), 7.09 (2H, m), 7.32 (1H, dd, J = 2 and 8 Hz), 7.41 (1H, d, J = 2 Hz), 7.83 (1H, s), 8.07 (2H, m); m/z (CI): 365 (MH⁺; 100%)

20 Example 52

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-methoxybenzamide

¹H NMR (CDCl₃) δ: 2.46 (3H, s), 2.69 (2H, t, J = 6 Hz), 2.90 (2H, t, J = 6 Hz), 3.57 (2H, s), 3.96 (3H, s), 7.09 (1H, d, J = 8 Hz), 7.30 (1H, dd, J = 2 and 8 Hz), 7.34 (1H, d, J = 2 Hz), 7.81 (2H, s), 7.89 (1H, s); m/z (CI): 365 (MH⁺; 100%)

Example 53

N-(2-Methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-ethoxybenzamide

30 ¹H NMR (CDCl₃) δ: 1.49 (3H, t, J = 7 Hz), 2.46 (3H, s), 2.69 (2H, t, J = 7 Hz), 2.90 (2H, t, J = 6 Hz), 3.56 (2H, s), 4.17 (2H, q, J = 7 Hz), 7.09 (1H, d, J = 8 Hz), 7.29 (1H, dd, J = 2 and 8 Hz), 7.32 (1H, s), 7.80 (2H, s), 7.86 (1H, s); m/z (CI): 379 (MH⁺; 100%)

Example 54

35 **N-(2-Methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-iso-propoxybenzamide**

¹H NMR (CDCl₃) δ: 1.39 (6H, d, J = 6 Hz), 2.47 (3H, s), 2.70 (2H, t, J = 6 Hz), 2.91 (2H, t, J = 6 Hz), 3.59 (2H, s), 4.72 (1H, quintet, J = 6 Hz), 7.10 (1H, d, J = 8 Hz), 7.30 (1H, dd, J = 2 and 8 Hz), 7.36 (1H, s), 7.76 (d, J = 2 Hz), 7.80 (2H, s).
m/z (CI): 393 (MH⁺, 100%)

5

Example 55**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonylbenzamide**

10 ¹H NMR (CDCl₃) δ: 2.48 (3H, s), 2.71 (2H, t, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.12 (3H, s), 3.60 (2H, s), 7.12 (1H, d, J = 8 Hz), 7.35 (1H, dd, J = 2 and 8 Hz), 7.42 (1H, s), 7.73 (1H, t, J = 8 Hz), 8.05 (1H, s), 8.11 (1H, d, J = 8 Hz), 8.22 (1H, d, J = 8 Hz), 8.40 (1H, s); m/z (CI): 345 (MH⁺; 100%)

Example 5615 **N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*tert*-butylbenzamide**

20 A solution of the amine D5 (162mg; 1.0 mmol) and 3-bromo-4-*tert*-butylbenzoic acid (257mg; 1.0 mmol) in anhydrous N,N-dimethylformamide (7ml), was treated with 1-hydroxybenzotriazole (135mg; 1.0 mmol) and 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (192mg; 1.0 mmol) at 25°C. The mixture was shaken for 48h before extracting the product into dichloromethane and washing with 10% aqueous NaHCO₃, water and finally brine. The organic layer was dried over MgSO₄ and evaporated *in vacuo* to afford 373mg of the title compound in 93% yield.

25 ¹H NMR (CDCl₃) δ: 1.54 (9H, s), 2.47 (3H, s), 2.71 (2H, t, J = 6 Hz), 2.91 (2H, t, J = 6 Hz), 3.60 (2H, s), 7.10 (1H, d, J = 8 Hz), 7.31 (1H, dd, J = 2 and 8 Hz), 7.41 (1H, d, J = 2 Hz), 7.54 (1H, d, J = 8 Hz), 7.72 (2H, m), 8.06 (1H, d, J = 2 Hz).

Example 5730 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromo-5-methoxybenzamide**

¹H NMR (CDCl₃) δ: 2.47 (3H, s), 2.70 (2H, t, J = 6 Hz), 2.91 (2H, t, J = 6 Hz), 3.61 (2H, s), 3.83 (3H, s), 6.88 (1H, dd), 7.11 (1H, d, J = 8 Hz), 7.21 (1H, d), 7.31 (1H, dd, J = 8, 2 Hz), 7.44 (1H, d), 7.50 (1H, d), 7.71 (1H, s); m/z (API⁺): 375.0 (MH⁺; 100%)

Example 58

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methoxybenzamide, hydrochloride

- 5 ^1H NMR (free base CDCl_3) δ : 2.53 (3H, s), 2.76 (2H, t, $J = 6$ Hz), 2.97 (2H, t, $J = 6$ Hz), 3.63 (2H, s), 4.01 (3H, s), 7.16 (1H, dd, $J = 6$, 2 Hz), 7.21 (1H, d), 7.32 - 7.50 (3H, m), 7.64 (1H, dd, $J = 6$, 2 Hz), 8.00 (1H, brs); m/z (API+): 315.1 (MH^+ ; 100%)

Example 59

- 10 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-1-methylpyrazole-4-carboxamide**

^1H NMR (250 MHz, CDCl_3) δ : 2.30 (3H, s), 2.53 (2H, m), 3.40 (2H, s), 3.78 (3H, s), 6.91 (1H, d, $J = 8$ Hz), 7.11 (1H, m), 7.21 (1H, d), 7.20 (1H, brs), 7.46 (1H, br), 7.68 (1H, s), 7.76 (1H, s); m/z (API+): 271 (MH^+ ; 100%)

15

Example 60

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethylpyrazole-3-carboxamide

- 20 ^1H NMR (250 MHz, D_6 DMSO) δ : 2.41 (3H, s), 2.81 - 2.85 (4H, m), 7.13 (1H, d, $J = 8$ Hz), 7.46 (2H, m), 8.64 (1H, s); m/z (API+): 325 (MH^+ ; 100%)

Example 61

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylthiazole-4-carboxamide

25

^1H NMR (250 MHz, CDCl_3) δ : 2.47 (3H, s), 2.67 - 2.76 (5H, m), 2.89 (2H, m), 3.60 (2H, s), 7.10 (1H, d, $J = 8$ Hz), 7.40 (1H, dd, $J = 8$, 2 Hz), 7.49 (1H, brs), 8.02 (1H, br), 9.12 (1H, br); m/z (API+): 288 (MH^+ ; 100%)

30 **Example 62**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-methylisoxazole-3-carboxamide

- 35 ^1H NMR (250 MHz, CDCl_3) δ : 2.46 (3H, s), 2.51 (3H, s), 2.68 (2H, m), 2.90 (2H, m), 3.58 (2H, s), 6.51 (1H, s), 7.10 (1H, d, $J = 8$ Hz), 7.33 (1H, dd, $J = 8$, 2 Hz), 7.41 (1H, brs), 8.47 (1H, brs); m/z (API+): 272 (MH^+ ; 100%)

Example 63**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-*tert*-butylisoxazole-3-carboxamide**

- 5 ^1H NMR (250 MHz, CDCl_3) δ : 1.38 (9H, s), 2.46 (3H, s), 2.66 - 2.71 (2H, m), 2.89 (2H, m), 3.59 (2H, s), 6.48 (1H, s), 7.10 (1H, d, $J = 8$ Hz), 7.30 (2H, brd, $J = 8$ Hz), 7.41 (1H, brs), 8.43 (1H, brs); m/z (API+): 314 (MH^+ ; 100%)

Example 64

- 10 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methoxyisoxazole-5-carboxamide hydrochloride**

^1H NMR (250 MHz, $\text{DMSO}-d_6$) δ : *inter alia* 2.81 (3H, brs), 3.88 (3H, s), 7.00 (1H, s), 7.16 (2H, d, $J = 8$ Hz), 7.52 (2H, m); m/z (API+): 288 (MH^+ ; 100%)

15

Example 65**N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)indole-2-carboxamide.**

- 20 D5 was converted into the title compound by reaction with indole-2-carboxylic acid, in a similar manner to the procedure of Description 7.

^1H NMR (D_6 DMSO) δ : 2.84 (3H, s), 3.07 (2H, t, $J = 6$ Hz), 3.29 (2H, t, $J = 6$ Hz), 3.97 (2H, s), 5.01 (1H, m), 7.53 (2H, m), 7.70 (2H, m), 8.08 (4H, m), 9.90 (1H, brs).
 m/z (API+): 306 (MH^+ ; 100%)

25

Example 66**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propylbenzamide, hydrochloride**

- 30 ^1H NMR (free base, CDCl_3) δ : 1.26 (6H, d, $J = 7$ Hz), 2.48 (3H, s), 2.75 (2H, m), 2.90 (2H, m), 3.41 (1H, sep, $J = 7$ Hz), 3.62 (2H, s), 7.09 (1H, d, $J = 8$ Hz), 7.31 (2H, dd, $J = 8, 2$ Hz), 7.37 (2H, m), 7.76 (1H, dd, $J = 8, 2$ Hz), 7.90 (1H, brs), 8.02 (1H, d, $J = 2$ Hz);
 m/z (API+): 387, 389 (MH^+ ; 100%)

Example 67

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propylbenzamide, hydrochloride

- 5 ^1H NMR (free base, CDCl_3) δ : 1.25 (6H, d, $J = 7$ Hz), 2.37 (3H, s), 2.60 (2H, m), 2.80 (2H, m), 3.45 (1H, sep, $J = 7$ Hz), 3.62 (2H, s), 7.00 (1H, d, $J = 8$ Hz), 7.25 (2H, m), 7.41 (1H, d), 7.97 (1H, dd, $J = 8, 2$ Hz), 8.03 (1H, d, $J = 2$ Hz), 8.10 (1H, brs); m/z (API+): 334 (MH^+ ; 100%)

10 **Example 68**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-4-methoxybenzamide

- ^1H NMR (250 MHz CDCl_3) δ : 2.48 (3H, s), 2.73 (2H, t, $J = 6$ Hz), 2.92 (2H, t, $J = 6$ Hz), 3.61 (2H, s), 3.96 (3H, s), 7.05 (2H, m), 7.30 (1H, dd, $J = 6, 2$ Hz), 7.40 (1H, s),
15 7.63 (2H, d), 7.80 (1H, d); m/z (API+): 315.2 (MH^+ ; 100%)

Example 69

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*n*-propoxybenzamide

- 20 ^1H NMR (250 MHz CDCl_3) δ : 1.10 (3H, t, $J = 8$ Hz), 1.92 (2H, m), 2.47 (3H, s), 2.70 (2H, t, $J = 6$ Hz), 2.90 (2H, t, $J = 6$ Hz), 3.58 (2H, s), 4.10 (2H, , $J = 8$ Hz), 7.02 (1H, d.), 7.09 (1H, d), 7.33 (1H, dd, $J = 6, 2$ Hz), 7.38 (1H, s), 8.02 (1H, s), 8.08 (2H, m); m/z (API+): 350.2 (MH^+ ; 100%)

25 **Example 70**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethoxybenzamide

- ^1H NMR (250 MHz CDCl_3) δ : 1.53 (3H, t, $J = 8$ Hz), 2.49 (3H, s), 2.74 (2H, t, $J = 6$ Hz), 2.92 (2H, t, $J = 6$ Hz), 3.62 (2H, s), 4.23 (2H, q, $J = 8$ Hz), 7.04 (1H, d), 7.10 (1H, d),
30 7.32 (1H, dd, $J = 6, 2$ Hz), 7.40 (1H, d), 7.92 (1H, s), 8.09 (2H, m); m/z (API+): 336.2 (MH^+ ; 100%)

Example 71

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*n*-propoxybenzamide

35

- ^1H NMR (250 MHz CDCl_3) δ : 1.10 (3H, t, $J = 8$ Hz), 1.90 (2H, m), 2.46 (3H, s), 2.69 (2H, t, $J = 6$ Hz), 2.90 (2H, t, $J = 6$ Hz), 3.58 (2H, s), 4.05 (2H, t, $J = 8$ Hz), 6.93 (1H, d),

7.09 (1H, d), 7.30 (1H, dd, J = 6, 2Hz), 7.39 (1H, d), 7.72 (1H, s), 7.80 (1H, dd, J = 6, 2Hz), 8.05 (1H, d); m/z (API+): 403.1 (MH⁺; 90%)

Example 72

5 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide

¹H NMR (250 MHz CDCl₃) δ: 1.26 (3H, t, J = 8 Hz), 2.46 (3H, s), 2.69 (2H, t, J = 6 Hz), 2.82 (2H, q, J = 8 Hz), 2.90 (2H, t, J = 6 Hz), 3.59 (2H, s), 7.10 (1H, d), 7.28 (1H, dd, J = 6, 2 Hz), 7.34 (1H, d), 7.41 (1H, d), 7.74 (2H, dd), 8.03 (1H, s);
10 m/z (API+): 373.1 (MH⁺; 100%)

Example 73

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-iodo-4-methoxybenzamide

15 ¹H NMR (250 MHz CDCl₃) δ: 2.50 (3H, s), 2.79 (2H, t, J = 6 Hz), 2.93 (2H, t, J = 6 Hz), 3.64 (2H, s), 3.94 (3H, s), 6.85 (1H, d), 7.21 (1H, d), 7.08 (1H, d), 7.34 (1H, dd, J = 6, 2Hz), 7.38 (1H, d), 7.89 (1H, dd), 8.12 (1H, s), 8.29 (1H, d);
 m/z (API+): 423.0 (MH⁺; 100%)

20 Example 74

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxy-3-trifluoromethyl benzamide

¹H NMR (250 MHz CDCl₃) δ: 1.39 (6H, d, J = 8 Hz), 2.48 (3H, s), 2.70 (2H, t, J = 6 Hz), 2.87 (2H, t, J = 6 Hz), 3.54 (2H, s), 4.72 (1H, m), 7.06 (2H, t), 7.30 (1H, dd, J = 6, 2Hz), 7.37 (1H, s), 8.03 (3H, m); m/z (API+): 393.2 (MH⁺; 100%)
25

Example 75

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-methoxybenzamide

30 ¹H NMR (250 MHz CDCl₃) δ: 2.47 (3H, s), 2.70 (2H, t, J = 6 Hz), 2.88 (2H, t, J = 6 Hz), 3.59 (2H, s), 3.98 (3H, s), 7.11 (1H, d), 7.21 (1H, d), 7.30 (2H, m), 7.40 (1H, d), 7.45 (1H, d), 7.75 (1H, s); m/z (API+): 331.1 (MH⁺; 100%)

Example 76

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxy-3-trifluoromethyl benzamide

- 5 ^1H NMR (250 MHz CDCl_3) δ : 1.08 (3H, t, $J = 8$ Hz), 1.86 (2H, m), 2.46 (3H, s), 2.70 (2H, t, $J = 6$ Hz), 2.90 (2H, t, $J = 6$ Hz), 3.58 (2H, s), 4.08 (2H, t, $J = 8$ Hz), 7.07 (2H, m), 7.29 (1H, dd, $J = 6, 2$ Hz), 7.41 (1H, d), 7.97 (1H, s), 8.03 (1H, d), 8.07 (1H, s); m/z (API+): 393.2 (MH^+ ; 100%)

10 **Example 77**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*tert*-butylbenzamide, hydrochloride

- 15 ^1H NMR (250 MHz, $\text{DMSO}-d_6$) δ : *inter alia* 1.68 (9H, s), 7.36 (1H, d, $J = 8$ Hz), 7.77 (3H, m), 8.00 (1H, dd, $J = 8, 2$ Hz), 8.11 (1H, d, $J = 2$ Hz); m/z (API+): 357 (MH^+ ; 100%)

Example 78

- 20 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxybenzamide hydrochloride.**

D5 was converted into the title compound in 95% yield by reaction with 4-methoxybenzoyl chloride in a manner similar to that described in Example 3.

- 25 ^1H NMR (D_2O) δ : 3.13 (3H, s), 3.25 (2H, brs), 3.68 (2H, brs), 3.96 (3H, s), 4.48 (2H, brs), 7.15 (2H, d, $J = 9$ Hz), 7.35-7.50 (3H, m), 7.90 (2H, d, $J = 9$ Hz).

Example 79

- 30 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methylbenzamide, hydrochloride**

^1H NMR (free base CDCl_3) δ : 2.34 (3H, s), 2.46 (3H, s), 2.69 (2H, t, $J = 6$ Hz), 2.90 (2H, t, $J = 6$ Hz), 3.58 (2H, s), 7.08 (2H, m), 7.30 (1H, dd), 7.40 (1H, d), 7.60 - 7.80 (2H, m), 7.74 (1H, s); m/z (API+): 299.2 (MH^+ ; 100%)

Example 80**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propylbenzamide**

¹H NMR (free base 250 MHz CDCl₃) δ: 1.40 (6H, d, J = 7 Hz), 2.59 (3H, s), 2.82 (2H, m), 3.03 (2H, m), 3.58 (1H, sep, J = 7 Hz), 3.71 (2H, s), 7.23 (1H, d, J = 8 Hz), 7.42 (1H, dd, J = 8, 2 Hz), 7.53 (2H, m), 7.82 (2H, m), 7.96 (1H, d, J = 2 Hz);
m/z (API+): 343, 345 (MH⁺; 100, 50%)

Example 81**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethylbenzamide hydrochloride**

¹H NMR (free base 250 MHz, CDCl₃) δ: 1.31 (3H, t, J = 8 Hz), 2.43 (3H, s), 2.66 (2H, m), 2.90 (4H, m), 3.55 (2H, s), 7.09 (1H, d, J = 8 Hz), 7.28 (2H, dd, J = 8, 2 Hz), 7.36 (1H, brs), 7.44 (1H, d, J = 8 Hz), 7.86 (1H, brs), 8.00 (1H, dd, J = 8, 2 Hz), 8.09 (1H, d, J = 2 Hz); m/z (API+): 320 (MH⁺; 100%)

Example 82**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propyl-3-trifluoromethylbenzamide hydrochloride**

¹H NMR (free base 250 MHz, CDCl₃) δ: *inter alia* 1.38 (6H, d, J = 6 Hz), 2.32 (3H, s), 2.57 (2H, m), 2.76 (2H, m), 3.25 (1H, m), 3.45 (2H, s), 6.95 (1H, d, J = 8 Hz), 7.16 (1H, brd, J = 8 Hz), 7.26 (1H, brs), 7.43 (1H, d, J = 8 Hz), 7.72 (1H, brs), 7.84 (1H, d, J = 8 Hz), 7.93 (1H, brs); m/z (API+): 377 (MH⁺; 100%)

Example 83**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-trifluoromethylbenzamide hydrochloride**

¹H NMR (free base 250 MHz, CDCl₃) δ: *inter alia* 1.25 (3H, t, J = 8 Hz), 2.46 (3H, s), 2.68 (2H, m), 2.90 (2H, m), 3.58 (2H, brs), 7.10 (1H, d, J = 8 Hz), 7.30 (1H, dd, J = 8, 2 Hz), 7.47 (1H, d, J = 8 Hz), 7.40 (1H, brs), 7.78 (1H, brs), 7.97 (1H, dd), 8.08 (1H, brs); m/z (API-): 361 (MH⁻; 100%)

Example 84**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propoxybenzamide hydrochloride**

- 5 ^1H NMR (250 MHz CDCl_3) δ : 1.45 (6H, d, $J = 8$ Hz), 2.47 (3H, s), 2.70 (2H, t, $J = 6$ Hz), 2.91 (2H, t, $J = 6$ Hz), 3.59 (2H, s), 4.75 (1H, m), 7.04 (1H, d), 7.10 (1H, d), 7.29 (1H, dd, $J = 6, 2$ Hz), 7.37 (1H, d), 7.71 (1H, s), 8.05 (2H, m); m/z (API $^+$): 350.2 (MH $^+$; 100%)

10 **Example 85**

N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide

- ^1H NMR (250 MHz CDCl_3) δ : 2.65 (2H, t, $J = 6$ Hz), 3.00 (2H, t, $J = 6$ Hz), 3.85 (3H, s), 3.89 (2H, s), 6.95 (2H, d), 7.17 (1H, dd, $J = 6, 2$ Hz), 7.25 (1H, s), 7.57 (1H, s), 7.93 (2H, m); m/z (API $^+$): 351.1 (MH $^+$; 100%)
- 15

Example 86**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methyl-3-methylsulfonylbenzamide**

- 20 ^1H NMR (CDCl_3) δ : 2.48 (3H, s), 2.71 (2H, t, $J = 7$ Hz), 2.80 (3H, s), 2.92 (2H, t, $J = 7$ Hz), 3.15 (3H, s), 3.61 (2H, s), 7.13 (2H, d), 7.35 (1H, dd), 7.43 (1H, s), 7.52 (1H, d), 7.93 (1H, s), 8.14 (1H, dd), 8.45 (1H, d); m/z (API $^+$): 359.2 (MH $^+$; 100%)

25 **Example 87**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-methylsulfonylbenzamide

- ^1H NMR (CDCl_3) δ : 1.49 (3H, t, $J = 8$ Hz), 2.59 (3H, s), 2.81 (2H, t, $J = 7$ Hz), 3.03 (2H, t, $J = 7$ Hz), 3.27 (5H, m), 3.71 (2H, s), 7.23 (2H, d), 7.46 (1H, dd), 7.54 (1H, d), 7.69 (1H, d), 8.04 (1H, s), 8.29 (1H, dd), 8.55 (1H, d); m/z (API $^+$): 373.2 (MH $^+$; 100%)
- 30

Example 88**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-*iso*-propylbenzamide**

- 35 ^1H NMR (CDCl_3) δ : 1.27 (6H, d, $J = 8$ Hz), 2.37 (3H, s), 2.60 (2H, t, $J = 7$ Hz), 2.81 (2H, t, $J = 7$ Hz), 3.06 (3H, s), 3.46 (2H, s), 3.85 (1H, m), 7.00 (2H, d), 7.26 (1H, dd), 7.31 (1H, d), 7.57 (1H, d), 8.10 (1H, dd), 8.21 (1H, s), 8.37 (1H, d);

m/z (API⁺): 387.2 (MH⁺; 100%)

Example 89

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-methoxybenzamide

¹H NMR (CDCl₃) δ : 2.31 (3H, s), 2.54 (2H, t, J = 7 Hz), 2.75 (2H, t, J = 7 Hz), 3.09 (3H, s), 3.42 (2H, s), 3.87 (3H, s), 6.95 (2H, m), 7.12 (1H, s), 7.21 (1H, d), 8.08 (2H, m), 8.23 (1H, d); m/z (API⁺): 375.2 (MH⁺; 75%)

Example 90

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoroacetylbenzamide, hydrochloride

¹H NMR (free base CDCl₃) δ : 2.47 (3H, s), 2.46 (3H, s), 2.77 (2H, t, J = 6 Hz), 2.94 (2H, t, J = 6 Hz), 3.63 (2H, s), 7.13 (1H, d, J = 6 Hz), 7.45 (1H, d, J = 6 Hz), 7.54 (1H, t, J = 6 Hz), 7.81 (1H, d, J = 6 Hz), 7.97 (1H, d, J = 6 Hz); 8.20 (1H, s); m/z (API⁺): 363.2 (MH⁺; 60%)

Example 91

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-pentafluoroethylbenzamide hydrochloride

¹H NMR (free base 250 MHz, CDCl₃) δ : 2.46 (3H, s), 2.70 (2H, m), 2.90 (2H, m), 3.59 (2H, s), 3.94 (3H, s), 7.10 (2H, m), 7.30 (1H, dd, J = 8, 2 Hz), 7.39 (1H, brs), 7.73 (1H, brs), 8.01 (1H, d, J = 2 Hz), 8.06 (1H, dd, J = 9, 2 Hz); m/z (API⁺): 415 (MH⁺; 100%)

Example 92

N-(2-n-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide

¹H NMR (CDCl₃) δ : 0.95 (3H, t, J = 7 Hz), 1.51 (3H, t, J = 7 Hz), 1.62 (2H, m), 2.47 (2H, t, J = 8 Hz), 2.72 (2H, t, J = 6 Hz), 2.88 (2H, t, J = 6 Hz), 3.61 (2H, s), 4.17 (2H, q, J = 7 Hz), 6.92 (1H, d, J = 9 Hz), 7.07 (1H, d, J = 8 Hz), 7.26 (1H, dd, J = 8, 2 Hz), 7.39 (1H, d, J = 2 Hz), 7.72 (1H, brs), 7.79 (1H, dd, J = 9, 2 Hz), 8.04 (1H, d, J = 2 Hz).

m/z (API⁺): 417, 419 (MH⁺; 95%)

Example 93**N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide**

- 5 ^1H NMR (CDCl_3) δ : 0.96 (3H, t, $J = 7$ Hz), 1.61 (2H, m), 2.47 (2H, t, $J = 8$ Hz), 2.73 (2H, t, $J = 6$ Hz), 2.88 (2H, t, $J = 6$ Hz), 3.62 (2H, s), 3.98 (3H, s), 7.08 (2H, m), 7.30 (1H, m), 7.41 (1H, d, $J = 2$ Hz), 7.76 (1H, brs), 8.05 (2H, m); m/z (API^+): 393 (MH^+ ; 100%)

10 **Example 94**

N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide

- 15 ^1H NMR (CDCl_3) δ : 0.95 (3H, t, $J = 7$ Hz), 1.42 (6H, d, $J = 6$ Hz), 1.62 (2H, m), 2.48 (2H, t, $J = 8$ Hz), 2.73 (2H, t, $J = 6$ Hz), 2.88 (2H, t, $J = 6$ Hz), 3.63 (2H, s), 4.66 (1H, sept., $J = 6$ Hz), 6.98 (1H, d, $J = 9$ Hz), 7.08 (1H, d, $J = 8$ Hz), 7.26 (1H, m), 7.41 (1H, d, $J = 2$ Hz), 7.65 (1H, brs), 7.73 (1H, dd, $J = 9, 2$ Hz), 7.87 (1H, d, $J = 2$ Hz).
 m/z (API^+): 387 (MH^+ ; 90%)

Example 95

- 20 **N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-butylbenzamide hydrochloride**

- 25 ^1H NMR (250 MHz, DMSO-d_6) δ : *inter alia* 0.95 (6H, d, $J = 7$ Hz), 1.99 (1H, sep, $J = 7$ Hz), 2.77 (2H, brs), 7.26 (1H, d, $J = 8$ Hz), 7.65 (3H, m), 8.21 (1H, dd, $J = 8, 2$ Hz), 8.41 (1H, d, $J = 8$ Hz); m/z (API^+): 348 (MH^+ ; 100%)

Example 96**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-butyl-3-trifluoromethylbenzamide hydrochloride**

- 30 ^1H NMR (250 MHz, DMSO-d_6) δ : *inter alia* 1.01 (6H, d, $J = 6.5$ Hz), 2.09 (1H, sep, $J = 6.5$ Hz), 7.35 (1H, d, $J = 8$ Hz), 7.75 (3H, m), 8.32 (1H, d, $J = 8$ Hz);
 m/z (API^+): 391 (MH^+ ; 100%)

Example 97**N-(2-Ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide**

- ¹H NMR (CDCl₃) δ: 1.20 (3H, t, J = 7 Hz), 1.51 (3H, t, J = 7 Hz), 2.61 (2H, q, J = 7 Hz), 2.76 (2H, m), 2.90 (2H, m), 3.64 (2H, s), 4.16 (2H, q, J = 7 Hz), 6.91 (1H, d, J = 9 Hz), 7.07 (1H, d, J = 8 Hz), 7.26 (1H, m), 7.40 (1H, d, J = 2 Hz), 7.79 (2H, m), 8.05 (1H, d, J = 2 Hz); m/z (API⁺): 403, 405 (MH⁺; 65%)

Example 98

- N-(2-Ethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-4-methoxy-3-trifluoromethyl benzamide**

- ¹H NMR (CDCl₃) δ: 1.21 (3H, t, J = 7 Hz), 2.65 (2H, q, J = 7 Hz), 2.80 (2H, d, J = 6 Hz), 2.92 (2H, t, J = 6 Hz), 3.67 (2H, s), 3.97 (3H, s), 7.07 (2H, m), 7.30 (1H, m), 7.41 (1H, d, J = 2 Hz), 7.89 (1H, brs), 8.06 (2H, m); m/z (API⁺): 379 (MH⁺; 100%)

Example 99**N-(2-iso-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide**

- ¹H NMR (CDCl₃) δ: 1.13 (6H, d, J = 7 Hz), 1.51 (3H, t, J = 7 Hz), 2.84 (5H, m), 3.71 (2H, s), 4.16 (2H, q, J = 7 Hz), 6.91 (1H, d, J = 9 Hz), 7.06 (1H, d, J = 8 Hz), 7.25 (1H, m), 7.42 (1H, d, J = 2 Hz), 7.78 (2H, m), 8.04 (1H, d, J = 2 Hz).
m/z (API⁺): 419 (MH⁺; 90%)

Example 100**N-(2-iso-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl benzamide**

- ¹H NMR (CDCl₃) δ: 1.13 (6H, d, J = 7 Hz), 2.84 (5H, m), 3.72 (2H, s), 3.97 (3H, s), 7.07 (2H, m), 7.26 (1H, m), 7.43 (1H, d, J = 2 Hz), 7.83 (1H, brs), 8.04 (2H, m)
m/z (API⁺): 393 (MH⁺; 100%)

Example 101**N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxy-3-methylsulfonyl-benzamide**

- 5 ¹H NMR (CDCl₃) δ: 1.52 (3H, t, J = 8 Hz), 2.46 (3H, s), 2.69 (2H, t, J = 7 Hz), 2.90 (2H, t, J = 7 Hz), 3.26 (3H, s), 3.57 (2H, s), 4.27 (2H, q, J = 7 Hz), 7.09 (2H, dd), 7.36 (1H, dd), 7.42 (1H, s), 7.83 (1H, brs), 8.12 (1H, s), 8.20 (1H, dd), 8.37 (1H, d); m/z (API⁺): 389.2 (MH⁺; 100%)

10 **Example 102**

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-oxochroman-6-carboxamide hydrochloride

- 15 ¹H NMR (D₆ DMSO) δ: 2.63 (3H, narrow d), 3.02 (2H, t, J = 7Hz), 3.14 (2H, brm), 3.60 (2H, brm), 4.54 (2h, brs), 4.77 (2H, d, J = 7 Hz), 7.25 (1H, m), 7.31 (1H, d, J = 8 Hz), 7.44 (2H, d, J = 6 Hz), 8.20 (1H, dd, J = 8, 2 Hz), 8.59 (1H, d, J = 2 Hz), 10.31 (1H, s), 10.95 (1H, brs); m/z (API⁺): 337.4 (MH⁺; 100%)

Example 103

- 20 **N-(2-Formyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide**

- 25 7-Amino-2-formyl-1,2,3,4-tetrahydroisoquinoline (0.176g) was converted into the title compound by reaction with 4-methoxy-3-trifluoromethylbenzoyl chloride, following the procedure of Example 3. The product was isolated as a white solid (0.035g).

- 30 ¹H NMR (d₆-DMSO) δ: 2.80 (2H, m), 3.65 (2H, broad t), 4.00 (3H, s), 4.59 (2H, d), 7.17 (1H, d, J = 8 Hz), 7.45 (1H, d, J = 8 Hz), 7.60 (2H, m), 8.26 (3H, m), 10.30 (1H, s). m/z (API⁺): 379 (MH⁺).

Example 104**N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide**

- 35 The compound D16 (115mg; 0.22 mmol) was dissolved in THF with stirring and tetrabutylammonium fluoride (1 M in THF; 0.216 mmol) added. The reaction was stirred overnight and the mixture purified by column chromatography through SiO₂, eluting with 10% methanol:dichloromethane. Trituration with petroleum ether, gave the title compound (48mg; 49%).

¹H NMR (250 MHz, CDCl₃) δ: 1.51 (3H, t, J = 7 Hz), 2.77 (2H, t, J = 5 Hz), 2.90 (4H, m, overlapping signal), 3.74 (4H, m, overlapping signal), 4.17 (2H, q, J = 7 Hz), 6.93 (1H, d, J = 10 Hz), 7.10 (1H, d, J = 8 Hz), 7.36 (1H, dd, J = 8, 2 Hz), 7.48 (1H, d, J = 2 Hz), 7.87 (1H, dd, J = 9, 2 Hz), 7.97 (1H, s), 8.08 (1H, d, J = 2 Hz)

Example 105

N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide

The title compound was prepared in 40% overall yield from D15 in a manner similar to that of Descriptions 16 and Example 106.

¹H NMR (250 MHz, CDCl₃) δ: 2.77 (10H, m, overlapping signals), 3.68 (5H, m, overlapping signals), 7.08 (1H, d, J = 8 Hz), 7.30 (2H, m, overlapping signals), 7.48 (1H, d, J = 2 Hz), 7.75 (1H, dd, J = 8, 2 Hz), 8.02 (1H, d, J = 2 Hz), 8.17 (1H, s).

Example 106

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenylmethoxy-3-trifluoromethyl benzamide

¹H NMR (CDCl₃) δ: 2.50 (3H, s), 2.75 (2H, t, J = 6 Hz), 2.94 (2H, t, J = 6 Hz), 3.64 (2H, s), 7.10 (2H, d, J = 8 Hz), 7.30 - 7.60 (7H, m, overlapping), 7.70 (1H, brs), 8.04 (1H, dd, J = 8, 2 Hz), 8.10 (1H, d, J = 2 Hz); m/z (CI): 441.2 (MH⁺; 100%)

Example 107

N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-hydroxy-3-trifluoromethyl benzamide

m/z (CI): 351.1 (MH⁺; 100%)

Example 108

N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-isopropoxybenzamide

¹H NMR (250 MHz, CDCl₃) δ: 1.41 (6H, d, J = 6 Hz), 2.75 (4H, t, overlapping, J = 6 Hz), 2.83 (2H, d, J = 5 Hz), 3.39 (3H, s), 3.61 (4H, t, overlapping, J = 6 Hz), 4.64

(1H,m), 6.91 (1H, d, J = 9 Hz), 7.01 (1H, d, J = 8 Hz), 7.20 (1H, dd, J = 8, 2 Hz), 7.29 (1H, d, J = 2 Hz), 7.80 (1H, dd, J = 9, 2 Hz), 8.07 (1H, d, J = 2 Hz), 8.10 (1H, s);
m/z (API+): 447, 449 (MH+, 90%)

5 **Example 109**

N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide

¹H NMR (250 MHz, CDCl₃) δ: 1.41 (6H, d, J = 6 Hz), 2.75 (4H, t, overlapping, J = 6 Hz), 2.83 (2H, d, J = 5 Hz), 3.39 (3H, s), 3.61 (4H, t, overlapping, J = 5 Hz), 4.64 (1H, m), 6.94 (1H, d, J = 9 Hz), 7.01 (1H, d, J = 8 Hz), 7.20 (1H, d, J = 8 Hz), 7.30 (1H, s), 7.75 (1H, dd, J = 9, 2 Hz), 7.90 (1H, d, J = 2 Hz); m/z (API+): 403, 405 (MH+)

Example 110

15 **N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide**

¹H NMR (250 MHz, CDCl₃) δ: 2.75 (4H, m), 2.85 (2H, d, J = 5 Hz), 3.39 (3H, s), 3.61 (4H, t, overlapping), 3.96 (3H, s), 7.04 (2H, m), 7.25 (1H, d, J = 10Hz), 7.35 (1H, s), 8.07 (3H, m); m/z (API+): 409 (MH+, 100%)

Example 111

25 (a) **N-(2-*t*-Butyloxycarbonyl-5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide**

The title compound was prepared in 81% yield from the acid Preparation 28 and amine D6.

30 (b) **N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide, trifluoroacetate.**

The title compound was prepared in 91% yield from using a method similar to that of Example 1.

35

m/z (CI): 420 (MH⁺; 100%).

Example 112**N-(2-Methyl-5-trifluoroacetyl-amino-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide**

The title compound (0.66g) was prepared from D25 (0.50g) and 3-bromo-4-methoxybenzoic acid (0.63g) using a procedure similar to that of Description 7.

m/z (CI): 486, 488 (MH^+ ; 90%).

Example 113**N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide**

m/z (CI): 425 (MH^+ ; expected isotope pattern).

Example 114**N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide**

1H NMR ($CDCl_3$) δ : 1.25 (3H, t, $J = 7Hz$), 2.48 (3H, s), 2.70-3.00 (6H, m, overlapping signals), 3.59 (2H, s), 7.29 (1H, d, $J = 2Hz$), 7.33 (1H, d, $J = 7Hz$), 7.51 (1H, d, $J = 2Hz$), 7.71 (1H, dd, $J = 7, 2Hz$), 7.83 (1H, brs), 8.01 (1H, d, $J = 2Hz$); m/z (CI): 409 (MH^+ ; expected isotope pattern).

PHARMACOLOGICAL DATA**1. Binding Assay Method**

WO 92/22293 (SmithKline Beecham) discloses compounds having anti-convulsant activity, including *inter alia* the compound *trans*-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham). The affinity of test compounds to the novel receptor site is assessed as follows.

Method

35

Whole forebrain tissue is obtained from rats. The tissue is first homogenised in buffer (usually 50mM Tris/HCl, pH 7.4). The homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at $-70^\circ C$ until used.

To carry out the radioligand binding assay, aliquots of tissue prepared as above (usually at a concentration of 1-2mg protein/ml) are mixed with aliquots of [3H]-Compound A dissolved in buffer. The final concentration of [3H]-Compound A in the mixture is usually 20nM. The mixture is incubated at room temperature for 1 hour. [3H]-Compound A bound to the tissue is then separated from unbound [3H]-Compound A by filtration through Whatman GF/B glass fibre filters. The filters are then washed rapidly with ice-cold buffer. The amount of radioactivity bound to the tissue trapped on the filters is measured by addition of liquid scintillation cocktail to the filters followed by counting in a liquid scintillation counter.

In order to determine the amount of "specific" binding of [3H]-Compound A, parallel assays are carried out as above in which [3H]-Compound A and tissue are incubated together in the presence of unlabelled Compound A (usually 3 μ M). The amount of binding of [3H]-Compound A remaining in the presence of this unlabelled compound is defined as "non-specific" binding. This amount is subtracted from the total amount of [3H]-Compound A binding (i.e. that present in the absence of unlabelled compound) to obtain the amount of "specific" binding of [3H]-Compound A to the novel site.

The affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested. The decrease in the level of specific [3H]-Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.

Results

Compounds of this invention were active in this test. For example, compounds of Examples 1, 4, 5, 6, 7, 10 and 13 gave pKi values greater than 7.

2. MEST Test

The maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties¹. In this model, anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.

Method for mouse model

Mice (naive male, Charles River, U.K. CD-1 strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC₅₀) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)². Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)³.

In control animals the CC₅₀ is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.

Studies are carried out using a Hugo Sachs Elektronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.

Results

Compounds of this invention dosed at 10 mg/kg by the oral route as a suspension in methyl cellulose and tested one hour post dosing showed an increase in seizure threshold. For example, the compounds of Examples 4, 5, 6 and 7 show increases of 24%, 36%, 90% and 23% respectively.

Method for rat model

The threshold for maximal (tonic hindlimb extension) electroshock seizures in male rats (Sprague Dawley, 80 - 150g, 6 weeks old) was determined by a Hugo Sachs Elektronik stimulator which delivered a constant current (0.3 sec duration; from 1-300mA in steps of 5-20mA). The procedure is similar to that outlined above for mouse and full details are as published by Upton et al.,⁴

The percentage increase or decrease in CC₅₀ for each group compared to the control is calculated.

Drugs are suspended in 1% methyl cellulose.

Results

- 5 At a dosage of 2 mg/kg p.o. at 2h, the compounds of Examples 48, 49, 51 and 67 show increases of 389%, 325%, 545% and 303% increases respectively.


References

- 10 1. Loscher, W. and Schmidt, D. (1988). *Epilepsy Res.*, **2**, 145-181
2. Dixon, W.J. and Mood, A.M. (1948). *J. Amer. Stat. Assn.*, **43**, 109-126
3. Litchfield, J.T. and Wilcoxon, F.(1949). *J. Pharmacol. exp. Ther.*, **96**, 99-113
4. N.Upton, T.P.Blackburn, C.A.Campbell, D.Cooper, M.L.Evans, H.J.Herdon, P.D.King,
A.M.Ray, T.O.Stean, W.N.Chan, J.M.Evans and M.Thompson. (1997). *B. J. Pharmacol.*,
15 **121**, 1679-1686

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

5



where Q is a monocyclic or bicyclic aryl or heteroaryl ring,

10 R^1 is hydrogen, , C₁₋₆ alkyl (optionally substituted by hydroxy or C₁₋₄alkoxy), C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆alkylCO-, formyl, CF₃CO- or C₁₋₆alkylSO₂-,

R^2 is hydrogen, hydroxy or up to three substituents selected from halogen, NO₂, CN, N₃,

15 CF₃O-, CF₃S-, CF₃CO-, trifluoromethyldiaziriny, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆perfluoroalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl-, C₁₋₆alkylO-, C₁₋₆alkylCO-, C₃₋₆cycloalkylO-, C₃₋₆cycloalkylCO-, C₃₋₆cycloalkyl-C₁₋₄alkylO-, C₃₋₆cycloalkyl-C₁₋₄alkylCO-, acetoxy, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C₁₋₄alkyl-, C₁₋₆alkylS-, C₁₋₆alkylSO₂-, (C₁₋₄alkyl)₂NSO₂-, (C₁₋₄alkyl)NHSO₂-, (C₁₋₄alkyl)₂NCO-, (C₁₋₄alkyl)NHCO- or CONH₂; or -NR³R⁴ where R³ is hydrogen or C₁₋₄ alkyl, and R⁴ is hydrogen, C₁₋₄alkyl, formyl, -CO₂C₁₋₄alkyl or -COC₁₋₄alkyl; or two R² groups together form a carbocyclic ring that is saturated or


20 unsaturated and unsubstituted or substituted by -OH or =O; and

25 X is hydrogen, halogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, amino or trifluoroacetyl amino; but when X is hydrogen excluding compounds in which R² is 2-alkoxy and when X is halogen excluding the compounds N-(7-iodo-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-benzoyl-2-methoxybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-4-trifluoromethyldiazirinybenzamide, N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-5-trifluoromethyldiazirinybenzamide,


30

N-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-2-methoxy-5-trifluoromethyldiaziriny benzamide and N-(8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-4-*t*-butyl-2-methoxybenzamide.

- 5 2. A compound of formula (IA) or (IB):



10



wherein R¹, R² and X are as defined in claim 1.

- 15 3. A compound selected from the group consisting of:
- N-(1,2,3,4-tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide
- N-(2-methyl-1, 2, 3, 4-tetrahydroisoquinolin-7-yl)-5-chlorothiophene-2-carboxamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chlorobenzamide
- 20 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*t*-butylbenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxybenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenoxybenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-nitrobenzamide
- 25 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylbenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluorobenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyanobenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dichlorobenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-iodobenzamide
- 30 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-bromobenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methylbenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-nitrobenzamide
- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide

- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-butylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-acetoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoromethylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-difluorobenzamide
 5 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-dimethoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-fluoro-4-trifluoromethyl benzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-nitrobenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-di-trifluoromethylbenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,4-dichloro-5-fluorobenzamide
 10 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-5-trifluoromethyl benzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4,5-trimethoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethoxybenzamide
 N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-pivaloylbenzamide
 15 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-acetoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopentyloxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-cyclopropylmethoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-methoxybenzamide
 20 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-naphthamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methylbenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-naphthalene-1-carboxamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-methoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*tert*-butoxybenzamide
 25 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl) benzotriazole-5-carboxamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl) benzothiazole-6-carboxamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2,3-dihydrobenzofuran-5-carboxamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylbenzimidazole-5-carboxamide
 30 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-ethoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl
 benzamide
 35 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-methoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-ethoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,5-dichloro-4-*iso*-propoxybenzamide
 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonylbenzamide

- N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*tert*-butylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromo-5-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methoxybenzamide,
hydrochloride
- 5 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-1-methylpyrazole-4-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-trifluoromethylpyrazole-3-
carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methylthiazole-4-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-methylisoxazole-3-carboxamide
- 10 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-*tert*-butylisoxazole-3-carboxamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methoxyisoxazole-5-carboxamide
hydrochloride
N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)indole-2-carboxamide.
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propylbenzamide,
hydrochloride
- 15 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*n*-propoxybenzamide
- 20 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*n*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-iodo-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propoxy-3-trifluoromethyl
- 25 benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-chloro-3-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*n*-propoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*tert*-butylbenzamide,
hydrochloride
- 30 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxybenzamide hydrochloride.
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-3-methylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propylbenzamide
- 35 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-ethylbenzamide
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-propyl-3-trifluoromethyl-
benzamide hydrochloride

- N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-trifluoromethylbenzamide
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-propoxybenzamide
hydrochloride
- 5 N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methyl-3-methylsulfonyl-benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethyl-3-methylsulfonylbenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-*iso*-
propylbenzamide
- 10 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-methylsulfonyl-4-methoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-trifluoroacetylbenzamide,
hydrochloride
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-pentafluoroethyl-
benzamide hydrochloride
- 15 N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-
trifluoromethylbenzamide
N-(2-*n*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-*iso*-butylbenzamide
hydrochloride
- 20 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-*iso*-butyl-3-trifluoromethyl-
benzamide hydrochloride
N-(2-Ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-Ethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-4-methoxy-3-trifluoromethyl benzamide
- 25 N-(2-*iso*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-*iso*-Propyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxy-3-methylsulfonyl-benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-oxochroman-6-carboxamide
hydrochloride
- 30 N-(2-Formyl--1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-
trifluoromethylbenzamide
N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
N-(2-Hydroxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide
- 35 N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-phenylmethoxy-3-trifluoromethyl
benzamide
N-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-hydroxy-3-trifluoromethyl benzamide


- N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-*iso*-propoxybenzamide
 N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-*iso*-propoxybenzamide
 5 N-(2-Methoxyethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide
 N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide, trifluoroacetate
 N-(2-Methyl-5-trifluoroacetyl-amino-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide
 10 N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide
 N-(2-Methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethylbenzamide

4. A pharmaceutical composition for use in the treatment and/or prophylaxis of
 15 anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia,
 20 Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate
 25 neuronal activity resulting in neurodysesthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) which comprises a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

- 30
 5. A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with
 35 anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including


circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof.

6. Use of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS)
7. A process for the preparation of a compound according to any one of claims 1 to 3, which comprises reacting a compound of formula (II)



where R^{1A} is R^1 as defined for formula (I) or a group convertible to R^1
and X is as defined in claim 1

- with a compound of formula (III)



- 5 where Q is as defined in formula (I), Y is Cl or OH, and R^{2A} groups are independently R² as defined for formula (I) or groups convertible to R²,
 and where required converting an R^{1A} or R^{2A} group to a R¹ or R² group,
 converting one R¹ or R² group to another R¹ or R² group,
 converting a salt product to the free base or another pharmaceutically acceptable salt, or
- 10 converting a free base product to a pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00782

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D217/04 A61K31/47 C07D217/02 C07D217/06 C07D409/12
C07D401/12 C07D417/12 C07D405/12 C07D413/12

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 022 900 A (MATHISON IAN WILLIAM) 10 May 1977 see the whole document ---	1,2,4-7
X	MATHISON I W ET AL: "SYNTHESIS AND HYPOTENSIVE PROPERTIES OF TETRAHYDROISOQUINOLINES" JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 4, 1973, pages 332-336, XP002040786 see the whole document ---	1,2,4-7
P, X	WO 97 48683 A (SMITHKLINE BEECHAM PLC) 24 December 1997 see claims -----	1,2,4-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 1998

Date of mailing of the international search report

07.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

national application No.

PCT/GB 98/ 00782

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 5
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4022900 A	10-05-1977	BE 763149 A	16-07-1971
		CH 550797 A	28-06-1974
		DE 2101691 A	16-03-1972
		FR 2106399 A	05-05-1972
		GB 1312205 A	04-04-1973
WO 9748683 A	24-12-1997	AU 3259597 A	07-01-1998